[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR20120024493A - A lentogenic newcastle disease virus and vaccine containing the same - Google Patents

A lentogenic newcastle disease virus and vaccine containing the same Download PDF

Info

Publication number
KR20120024493A
KR20120024493A KR1020110088716A KR20110088716A KR20120024493A KR 20120024493 A KR20120024493 A KR 20120024493A KR 1020110088716 A KR1020110088716 A KR 1020110088716A KR 20110088716 A KR20110088716 A KR 20110088716A KR 20120024493 A KR20120024493 A KR 20120024493A
Authority
KR
South Korea
Prior art keywords
leu
ser
thr
ala
val
Prior art date
Application number
KR1020110088716A
Other languages
Korean (ko)
Other versions
KR101371365B1 (en
Inventor
모인필
심종보
윤인중
유성식
최환원
Original Assignee
주식회사 중앙백신연구소
충북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 중앙백신연구소, 충북대학교 산학협력단 filed Critical 주식회사 중앙백신연구소
Publication of KR20120024493A publication Critical patent/KR20120024493A/en
Application granted granted Critical
Publication of KR101371365B1 publication Critical patent/KR101371365B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/125—Newcastle disease virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PURPOSE: A vaccine containing new castle diseases virus is provided to ensure excellent safety and efficiency. CONSTITUTION: A new castle disease virus contains F proteins. The virus contains nucleic acid encoding amino acid sequence of sequence number 2 or 3. The new castle disease virus contains HN proteins. A vaccine for new castle virus contains the new castle virus. The vaccine is a live vaccine, attenuated vaccine, or inactivated vaccine. The vaccine prevents new castle disease by administering to chicken, duck, turkey, quail or ostrich. A composition for diagnosing new castle virus contains an antibody which specifically recognizes the virus.

Description

저병원성 뉴캐슬병 바이러스 및 이를 포함하는 뉴캐슬병 바이러스용 백신 {A LENTOGENIC NEWCASTLE DISEASE VIRUS AND VACCINE CONTAINING THE SAME}Low pathogenic Newcastle disease virus and vaccine for Newcastle disease virus comprising the same {A LENTOGENIC NEWCASTLE DISEASE VIRUS AND VACCINE CONTAINING THE SAME}

본 발명은 뉴캐슬병 바이러스, 이를 포함하는 뉴캐슬병 바이러스용 백신, 이를 특이적으로 인식하는 항체, 상기 항체를 포함하는 뉴캐슬병 바이러스 진단용 조성물, 뉴캐슬병 바이러스의 진단에 관한 정보를 제공하는 방법 및 키트에 관한 것이다.
The present invention relates to a Newcastle disease virus, a vaccine for Newcastle disease virus comprising the same, an antibody that specifically recognizes the same, a composition for diagnosing Newcastle disease virus comprising the antibody, a method and kit for providing information regarding the diagnosis of Newcastle disease virus.

뉴캐슬병(Newcastle disease)은 가금에서 치명적이고 전염성이 강한 제 1종 가축 전염병으로 백신을 접종하지 않은 닭에 감염될 때는 100% 폐사율을 초래하며, 적절한 백신을 하지 않는 경우 호흡기 및 소화기 증상과 산란계에서 산란율 저하로 경제적인 피해를 일으키는 치명적인 질병이다. 적절한 백신을 접종하지 않은 경우 백신 항체가가 낮은 산란계나 종계는 산란율이 떨어지거나 중지되기도 한다. 또한 예방 접종을 했더라도 접종 시기나 방법이 잘못되어 항체가가 높지 않은 닭에서는 다리와 목이 마비되는 신경증상이 나타기도 한다.Newcastle disease is a lethal, highly contagious livestock epidemic in poultry, with a 100% mortality rate when infected with unvaccinated chickens. If not properly vaccinated, respiratory and digestive symptoms and laying rates in laying hens It is a deadly disease that causes economic damage from degradation. Laying hens or breeders with low vaccine antibody titers may lower or stop laying if the vaccine is not vaccinated. In addition, even if the vaccination is a wrong time or method of vaccination in chickens with high antibody value may cause neurological symptoms of paralysis of the legs and neck.

우리나라는 뉴캐슬병 바이러스(Newcastle disease virus, NDV) 상재지역으로, 매년 발생주의보를 발표하고 있으나 발생이 계속 증가하고 전국적으로 발생되는 추세에 있으며 양계 농가에 큰 피해를 주고 있다. 또한, 우리나라와 활발한 교역을 하고 있는 동남아시아, 중국, 및 대만에는 다양한 뉴캐슬병 바이러스들이 유행하고 있어서 잠재적인 위해 요인으로 존재하므로, 아시아형 뉴캐슬병 백신의 개발이 절실한 시점이다.Korea is a Newcastle disease virus (NDV) commodity region, which publishes an advisory report every year, but the number of occurrences continues to increase and occurs nationwide. In addition, as Southeast Asia, China, and Taiwan, which are actively trading with Korea, various Newcastle disease viruses are prevalent, there is a potential risk factor, and development of Asian type Newcastle disease vaccines is urgently needed.

뉴캐슬병 바이러스는 단일 가닥(single stranded) RNA 바이러스로 아부라바이러스 속(genus Avulavirus)에 속한다. 뉴캐슬병 바이러스는 엔벨롭(envelope)을 가지고 있으며 엔벨롭에는 바이러스가 숙주 세포에 결합할 수 있도록 해주는 HN(Haemagglutinin-Neuraminidase) 단백질과 엔벨롭과 숙주 세포의 융합을 일으키는 F(Fusion) 단백질이 있다. F 단백질과 HN 단백질은 글리코단백질(glycoprotein)로서 엔벨롭의 표면에 분포되어 있다. 뉴캐슬병 바이러스는 F 유전자의 염기서열의 계통분석에 의해 I부터 VIII까지의 유전형으로 분류된다:Newcastle disease virus is a single stranded RNA virus belonging to the genus Avulavirus. The Newcastle disease virus has an envelope, which contains the Haemagglutinin-Neuraminidase (HN) protein, which allows the virus to bind to the host cell, and the F (Fusion) protein, which causes the envelope and host cell to fuse. F protein and HN protein are glycoproteins distributed on the surface of the envelope. Newcastle disease viruses are classified into genotypes I through VIII by phylogenetic analysis of the nucleotide sequence of the F gene:

Figure pat00001
Figure pat00001

F 단백질은 Ⅰ형 막 글리코단백질(type Ⅰ membrane glycoprotein)로써 삼합체(trimeric) 구조를 형성한다. F 단백질은 비활성 전구체 형태(F0)로 만들어지고 골지 막(Golgi membranes)을 통해 이동하는 동안 활성 형태인 F1과 F2로 잘리게 된다. 이러한 과정은 F1 소단위체(subunit)의 아미노 말단에서 소수성 도메인(domain)을 노출시키고 이것은 성숙한 단백질의 생물학적 활성에 중요한 역할을 한다. 융합 펩티드(fusion peptide)라 불리는 소수성 도메인은 파라믹소바이러스(paramyxovirus) F 단백질에서 매우 보존되어 있고 막 융합을 매개하는데 직접적으로 관여하고 있을 것이라 여겨지고 있다. 파라믹소바이러스 F 단백질은 7개 반복(heptad repeats)을 포함하고 알파 헬릭스 구조를 형성할 가능성이 있는 두 지역을 포함하는 여러 개의 공통된 구조 형태를 갖고 있다. 두 반복중 가장 긴 7개 반복 A(heptad repeat A)는 F1의 아미노 말단에서 소수성 융합 펩티드와 인접해 있으며, 7개 반복 B는 관통막(transmembrane) 지역의 윗부분에 밀착하여 있다. 7개 반복 B는 매 7개 잔기마다 매우 보존된 류신 또는 이소류신의 연속으로 구성되어 있다.F protein is a type I membrane glycoprotein and forms a trimeric structure. The F protein is made into the inactive precursor form (F0) and is cut into the active forms F1 and F2 while traveling through the Golgi membranes. This process exposes a hydrophobic domain at the amino terminus of the F1 subunit, which plays an important role in the biological activity of mature proteins. Hydrophobic domains, called fusion peptides, are highly conserved in the paramyxovirus F protein and are believed to be directly involved in mediating membrane fusion. Paramyxovirus F proteins have several common structural forms, including two regions that contain seven heptad repeats and are likely to form alpha helix structures. The longest of the two repeats, heptad repeat A, is adjacent to the hydrophobic fusion peptide at the amino terminus of F1, and the seven repeats B are close to the top of the transmembrane region. Seven repeats B consist of a series of highly conserved leucine or isoleucine at every seven residues.

이러한 뉴캐슬병에 대한 예방을 위해 현재는 뉴캐슬 바이러스 B1 주, 뉴캐슬 바이러스 라소타(Lasota) 주 등과 같이 병원성이 거의 없는 약독화된 뉴캐슬 바이러스를 이용하여 생백신 또는 사독(불활화) 백신을 제조하여 뉴캐슬병의 예방백신으로 사용하고 있다. 강병원성 뉴캐슬병 바이러스를 이용한 불활화 백신은 안전성 문제 때문에 제조가 금지 되어 있다.For the prevention of Newcastle disease, a live or deadly inactivated vaccine is prepared by using attenuated Newcastle virus with little pathogenicity such as Newcastle Virus B1 and Newcastle Virus Lasota. It is used as a vaccine. Inactivated vaccines using the highly pathogenic Newcastle disease virus are banned due to safety concerns.

사독백신은 한마리씩 주사하여 접종하며, 생백신은 물에 타서 전체에 동시 투여하는 음수접종법, 여러마리를 한곳에 모은 후 적당량의 증류수에 희석한 백신을 분무하는 방법 또는 증류수에 희석한 백신을 한 마리씩 눈에 떨어뜨리는 점안 접종법 등으로 사용되고 있다.Zadok vaccine is injected by injecting one by one, and live vaccine is inoculated by water and administered simultaneously to the whole, by collecting several in one place and spraying the diluted vaccine in a suitable amount of distilled water or by diluting the vaccine diluted in distilled water one by one It is used by eye drops and inoculation methods.

이러한 방법들 중에서 보편적으로 쓰이는 방법은 사독백신주사법과 생백신 음수접종법이며 3일령 이내의 어린 병아리에는 분무접종법도 때때로 이용되고 있다. 생백신의 음수접종법과 분무접종법은 다른 접종방법에 비하여 노동력이 절감되고 사용방법이 간편하다는 이점 때문에 양계농가에서 가장 많이 사용되고 있는 방법이다.Among these methods, the most commonly used methods are vaccine injection and live vaccine negative vaccination, and spray vaccination is sometimes used for young chicks within 3 days of age. Negative vaccination and spray vaccination of live vaccines are the most widely used methods in poultry farms due to the advantages of reduced labor and simpler use compared to other vaccination methods.

그러나 불활화 백신의 경우, 생산하고 적용하는데 비용이 비싼 단점이 있다. 생백신의 경우, 약독화 백신이라고 하더라도 여전히 약간의 병원성을 가지고 있어 경우에 따라 백신 부작용이 나타날 수 있다. 게다가, 모계로부터 물려받은 항체들이 생백신 바이러스를 중화하여 성공적인 면역 형성이 방해 될 수 있다. 따라서 보다 안전하고, 경제적이며, 야외주와 유사한 항원성을 보이는 뉴캐슬병 백신 생산기술의 필요성이 증대되고 있다. However, inactivated vaccines have the disadvantage of being expensive to produce and apply. In the case of live vaccines, even attenuated vaccines still have some pathogenicity, which can lead to vaccine side effects. In addition, antibodies inherited from the mother system can neutralize live vaccine viruses, preventing successful immune formation. Therefore, there is an increasing need for Newcastle disease vaccine production technology that is safer, more economical, and has similar antigenicity to outdoor wine.

본 발명자들은 신규 백신주 개발을 위한 연구를 거듭한 결과, 새로운 저병원성 뉴캐슬병 바이러스를 발견하였으며, 상기 저병원성 뉴캐슬병 바이러스를 유효성분으로 포함하는 뉴캐슬병 예방용 백신을 개발하여 본 발명을 완성하였다.
As a result of repeated studies for the development of a new vaccine strain, the present inventors have discovered a new low-pathogenic Newcastle disease virus, and completed the present invention by developing a vaccine for preventing Newcastle disease including the low-pathogenic Newcastle disease virus as an active ingredient.

본 발명의 목적은 신규한 뉴캐슬병 바이러스 및 이를 포함하는 뉴캐슬병 바이러스용 백신을 제공하는 것이다.It is an object of the present invention to provide a novel Newcastle Disease Virus and a vaccine for Newcastle Disease Virus comprising the same.

본 발명의 또 다른 목적은 상기 백신을 인간을 제외한 개체에 투여하여 뉴캐슬병 바이러스 감염 질환을 예방 또는 치료하는 방법을 제공하는 것이다.Still another object of the present invention is to provide a method for preventing or treating Newcastle disease virus infectious disease by administering the vaccine to an individual except a human.

본 발명의 또 다른 목적은 본 발명의 신규한 뉴캐슬병 바이러스를 특이적으로 인식하는 항체를 제공하는 것이다.Another object of the present invention is to provide an antibody that specifically recognizes the novel Newcastle Disease virus of the present invention.

본 발명의 또 다른 목적은 항체를 포함하는 뉴캐슬병 바이러스 진단용 조성물을 제공하는 것이다.Still another object of the present invention is to provide a composition for diagnosing Newcastle Disease virus comprising an antibody.

본 발명의 또 다른 목적은 상기 항체를 포함하는 뉴캐슬병 바이러스 치료제를 제공하는 것이다.Still another object of the present invention is to provide a Newcastle disease virus therapeutic agent comprising the antibody.

본 발명의 또 다른 목적은 상기 항체를 뉴캐슬병 바이러스를 포함하는 시료에 반응시키고, 상기 항체에 대한 양성반응을 나타내는 시료를 뉴캐슬병으로 판단하는 것을 포함하는 뉴캐슬병 바이러스의 진단에 관한 정보를 제공하는 방법을 제공하는 것이다.It is another object of the present invention to provide a method for providing information regarding the diagnosis of Newcastle disease virus, comprising reacting the antibody with a sample containing Newcastle disease virus and judging that the sample showing positive response to the antibody is Newcastle disease. It is.

본 발명의 또 다른 목적은 상기 항체를 포함하는 뉴캐슬병 바이러스 진단용 키트를 제공하는 것이다.Still another object of the present invention is to provide a kit for diagnosing Newcastle Disease virus comprising the antibody.

본 발명은 서열번호 1의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 F 단백질을 포함하는 뉴캐슬병 바이러스를 제공한다. 본 발명의 일 구체예에서는 상기 서열번호 1과 96% 이상 상동성을 가지는 아미노산 서열은 서열번호 2 또는 서열번호 3이고, 서열번호 1의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 F 단백질을 코딩하는 핵산을 포함하고, 서열번호 2 또는 서열번호 3의 아미노산 서열을 코딩하는 핵산을 포함한다.The present invention provides Newcastle Disease Virus, which is represented by the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 96% homology therewith and which comprises an F protein having equivalent immunogenicity. In one embodiment of the present invention the amino acid sequence having at least 96% homology with SEQ ID NO: 1 is SEQ ID NO: 2 or SEQ ID NO: 3, the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 96% homology with it And nucleic acids encoding the F protein shown and having equivalent immunogenicity, and nucleic acids encoding the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.

본 발명의 일 실시예에서는 서열번호 4의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 HN 단백질을 포함하는 뉴캐슬병 바이러스를 제공한다. 본 발명의 일 구체예에서는 상기 서열번호 4와 96% 이상 상동성을 가지는 아미노산 서열은 서열번호 5 또는 서열번호 6이고, 서열번호 4의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 HN 단백질을 코딩하는 핵산을 포함하고, 서열번호 5 또는 서열번호 6의 아미노산 서열을 코딩하는 핵산을 포함한다.In one embodiment of the present invention provides a Newcastle disease virus represented by the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 96% homology with the HN protein having an equivalent immunogenicity. In one embodiment of the present invention the amino acid sequence having at least 96% homology with SEQ ID NO: 4 is SEQ ID NO: 5 or SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 96% homology with it And includes nucleic acids encoding HN proteins that are indicated and have equivalent immunogenicity, and that encode the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.

본 발명의 일 실시예에서는 서열번호 1의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 F 단백질 및 서열번호 4의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 HN 단백질을 포함하는 뉴캐슬병 바이러스를 제공한다. 본 발명의 일 구체예에서는 상기 서열번호 1의 아미노산 서열과 96% 이상 상동성을 가지는 아미노산 서열은 서열번호 2 또는 서열번호 3이고, 상기 서열번호 4의 아미노산 서열과 96% 이상 상동성을 가지는 아미노산 서열은 서열번호 5 또는 서열번호 6이며, 서열번호 1의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 F 단백질을 코딩하는 핵산 및 서열번호 4의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 HN 단백질을 코딩하는 핵산을 포함하고, 서열번호 2 또는 서열번호 3의 아미노산 서열을 코딩하는 핵산을 포함하고, 서열번호 5 또는 서열번호 6의 아미노산 서열을 코딩하는 핵산을 포함한다.In one embodiment of the present invention is represented by the amino acid sequence of SEQ ID NO: 1 or more than 96% homology with the amino acid sequence of SEQ ID NO: 1 and the amino acid sequence of SEQ ID NO: 4 or more than 96% homology with the amino acid sequence of SEQ ID NO: 4 Provided is a Newcastle disease virus represented by an amino acid sequence having an HN protein having equivalent immunogenicity. In one embodiment of the invention the amino acid sequence having at least 96% homology with the amino acid sequence of SEQ ID NO: 1 is SEQ ID NO: 2 or SEQ ID NO: 3, the amino acid having at least 96% homology with the amino acid sequence of SEQ ID NO: The sequence is SEQ ID NO: 5 or SEQ ID NO: 6, represented by the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 96% homology therewith, and the nucleic acid encoding the F protein having the equivalent immunogenicity and the amino acid sequence of SEQ ID NO: 4 Or a nucleic acid encoding an amino acid sequence having at least 96% homology therewith and encoding an HN protein having equivalent immunogenicity, and comprising a nucleic acid encoding an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3, SEQ ID NO: Nucleic acids encoding the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.

본 발명의 일 실시예에서는 상기 바이러스 중 하나를 포함하는 뉴캐슬병 바이러스용 백신을 제공한다. 본 발명의 일 구체예에서 상기 백신은 생백신, 약독화 백신, 또는 사독 백신인 것을 특징으로 하고, 상기 백신은 닭, 꿩, 오리, 칠면조, 메추리 또는 타조에 투여하여 뉴캐슬병을 예방하는 것을 특징으로 한다.In one embodiment of the present invention provides a vaccine for Newcastle disease virus comprising one of the viruses. In one embodiment of the invention the vaccine is characterized in that the live vaccine, attenuated vaccine, or dead poison vaccine, the vaccine is characterized in that the administration of chicken, pheasant, duck, turkey, quail or ostrich to prevent Newcastle disease .

본 발명의 일 실시예에서는 상기 백신을 인간을 제외한 개체에 투여하여 뉴캐슬병 바이러스 감염 질환을 예방 또는 치료하는 방법을 제공한다.An embodiment of the present invention provides a method for preventing or treating Newcastle disease virus infectious disease by administering the vaccine to a subject other than a human.

본 발명의 일 실시예에서는 상기 바이러스를 특이적으로 인식하는 항체를 제공한다.In one embodiment of the present invention provides an antibody that specifically recognizes the virus.

본 발명의 일 실시예에서는 상기 항체를 포함하는 뉴캐슬병 바이러스 진단용 조성물을 제공한다.In one embodiment of the present invention provides a composition for diagnosing Newcastle Disease virus comprising the antibody.

본 발명의 일 실시예에서는 상기 항체를 포함하는 뉴캐슬병 바이러스 치료제를 제공한다.In one embodiment of the present invention provides a Newcastle disease virus therapeutic agent comprising the antibody.

본 발명의 일 실시예에서는 상기 항체를 뉴캐슬병 바이러스를 포함하는 시료에 반응시키고, 상 기 항체에 대한 양성반응을 나타내는 시료를 뉴캐슬병으로 판단하는 것을 포함하는 뉴캐슬병 바이러스의 진단에 관한 정보를 제공하는 방법을 제공한다.In one embodiment of the present invention there is provided a method for providing information regarding the diagnosis of Newcastle disease virus comprising the reaction of the antibody to a sample containing Newcastle disease virus, and judging the sample showing a positive response to the antibody as Newcastle disease to provide.

본 발명의 일 실시예에서는 상기 항체를 포함하는 뉴캐슬병 바이러스 진단용 키트를 제공한다.In one embodiment of the present invention provides a Newcastle disease virus diagnostic kit comprising the antibody.

본 발명의 뉴캐슬병 바이러스는 기존의 상용화 생백신보다 저병원성을 갖고 있어 뉴캐슬병 생백신으로 사용하기에 매우 안전하며, 역가, 방어율 및 지속성이 더욱 우수하므로 안전성 및 유효성이 뛰어난 백신으로 활용할 수 있다.
The Newcastle disease virus of the present invention has a lower pathogenicity than conventional commercial live vaccines, and thus is very safe to use as a Newcastle disease live vaccine, and thus can be used as a vaccine having excellent safety and efficacy because it has better titer, protection rate and persistence.

이하, 본 발명의 구성요소와 기술적 특징을 다음의 실시예들을 통하여 보다 상세하게 설명하고자 한다. 그러나 하기 실시예들은 본 발명의 내용을 예시하는 것일 뿐 발명의 범위가 실시예에 의해 한정되는 것은 아니다.
Hereinafter, the components and technical features of the present invention will be described in more detail with reference to the following examples. However, the following examples are merely to illustrate the content of the present invention is not limited to the scope of the invention.

실시예Example

실시예1Example 1 : 바이러스 균주의 분리(: Isolation of Virus Strains CBU2179CBU2179 , , CBU2249CBU2249 및  And CBU2374CBU2374 ))

충북대학교 조류질병학 실험실에서, 2007년 전북 익산시 웅포면 능포리에서 철새(청둥오리, 쇠오리)로부터 새로운 뉴캐슬바이러스인 CBU2179, CBU2249 및 CBU2374를 분리하였다. 상기 분리된 바이러스는 한국생명공학연구원 생물자원센터(KCTC; Korean Collection for Type Cultures)에 기탁하였다(CBU2179: 기탁번호 KCTC11530BP, CBU2249: 기탁번호 KCTC11111BP, CBU2374: 기탁번호 KCTC22222BP).
In the bird disease laboratory at Chungbuk National University, the new Newcastle viruses CBU2179, CBU2249 and CBU2374 were isolated from migratory birds (mallards, ducks) in Neungpo-myeon, Iksan-si, Jeonbuk, Korea in 2007. The isolated virus was deposited in Korea Biotechnology Center (KCTC; Korean Collection for Type Cultures) (CBU2179: accession number KCTC11530BP, CBU2249: accession number KCTC11111BP, CBU2374: accession number KCTC22222BP).

실시예2Example 2 : 바이러스 균주의 확인: Identification of Virus Strains

<2-1> 유전자 서열 확인
<2-1> Gene Sequence Identification

정제된 바이러스 CBU2179, CBU2249 및 CBU2374의 유전자를 중합효소연쇄반응(polymerase chain reaction, PCR) 법으로 증폭한 다음 직접순서결정법(direct sequencing)으로 분석한 결과, 서열번호 7 내지 12가 확인되었으며, 서열번호 7은 CBU2249의 F단백질을 코딩하는 염기서열, 서열번호 8은 CBU2179의 F단백질을 코딩하는 염기서열, 서열번호 9는 CBU2374의 F단백질을 코딩하는 염기서열이고, 서열번호10은 CBU2249의 HN단백질을 코딩하는 염기서열, 서열번호 11은 CBU2179의 HN단백질을 코딩하는 염기서열, 서열번호 12는 CBU2374의 HN단백질을 코딩하는 염기서열이다. The genes of the purified viruses CBU2179, CBU2249 and CBU2374 were amplified by polymerase chain reaction (PCR) method and analyzed by direct sequencing. As a result, SEQ ID Nos. 7 to 12 were identified. 7 is the nucleotide sequence encoding the F protein of CBU2249, SEQ ID NO: 8 is the nucleotide sequence encoding the F protein of CBU2179, SEQ ID NO: 9 is the nucleotide sequence encoding the F protein of CBU2374, SEQ ID NO: 10 is the HN protein of CBU2249 The base sequence to be encoded, SEQ ID NO: 11 is the nucleotide sequence encoding the HN protein of CBU2179, SEQ ID NO: 12 is the nucleotide sequence encoding the HN protein of CBU2374.

<2-2> 바이러스 균주 타입 확인
<2-2> Virus strain type confirmation

CBU2179는 계통 분석(Phylogenetic analysis)과 같은 방법으로 유전자 분석을 수행한 결과, I형에 속하는 것으로 확인되었다.Genetic analysis of CBU2179 was performed in the same manner as Phylogenetic analysis and found to belong to type I.

또한, CBU2249 및 CBU2374를 분석한 결과 I형에 속하는 것으로 확인되었다.In addition, analysis of CBU2249 and CBU2374 confirmed that it belongs to type I.

또한, CBU2179 및 CBU2374의 F 단백질 의 아미노산 서열은 CBU2249의 F 단백질의 아미노산 서열과 각각 99% 이상의 상동성을 갖고, CBU2179 및 CBU2374의 HN 단백질의 아미노산 서열은 CBU2249의 HN 단백질의 아미노산 서열과 각각 99% 및 98% 이상의 상동성을 갖고 있음을 확인할 수 있었다.
Further, the amino acid sequence of the F protein of CBU2179 and CBU2374 has more than 99% homology with the amino acid sequence of the F protein of CBU2249, respectively, and the amino acid sequence of the HN protein of CBU2179 and CBU2374 is 99% of the amino acid sequence of the HN protein of CBU2249, respectively. And 98% or more homology.

실시예3Example 3 : 병원성 비교 실험: Pathogenicity Comparison Experiment

CBU2179, CBU2249 및 CBU2374와 종래 생백신 균주의 병원성을 비교하기 위해, Mean Death Time (MDT), Intracerebral pathogenicity index (ICPI) 방법으로 병원성을 측정하였으며, 종래 생백신 균주로는 VG/GA 및 B-1 주를 이용하였다. VG/GA 및 B-1 주는 이 백신주를 이용하여 제품화된 타사 백신을 구입하여 이것을 종란 접종법으로 증식하여 사용하였다.
To compare the pathogenicity of CBU2179, CBU2249, and CBU2374 with conventional live vaccine strains, pathogenicity was measured by Mean Death Time (MDT), Intracerebral pathogenicity index (ICPI) method, and VG / GA and B-1 strains were used as conventional live vaccine strains. Was used. VG / GA and B-1 strains were purchased using a third-party vaccine that was commercialized using this vaccine strain, and used to proliferate by egg seeding inoculation.

구체적으로는, 상기 실시예 1에서 분리한 CBU 2179, CBU2249 및 CBU2374 주와 비교예로서 VG/GA 주(비교예 1)및 B-1 주(비교예 2)를 10배 희석배수로 희석한 후, 상기 희석액을 9~10일령의 SPF(specific pathogen free) 종란에 요막강 경로로 각각 접종하여 7일간 관찰하면서 계태아가 죽는 시간을 측정하였다. 계태아의 폐사 시간에 따라 60시간 이전에 폐사한 경우, 60~90시간 사이에 폐사한 경우, 90시간 이후에 죽을 경우를 각각 고병원성(velogenic), 중간병원성(mesogenic), 저병원성(lentogenic)으로 분류하였다. 그 결과는 다음 표 1과 같다. Specifically, after diluting the VG / GA strain (Comparative Example 1) and the B-1 strain (Comparative Example 2) with the CBU 2179, CBU2249 and CBU2374 strain isolated in Example 1 in a 10-fold dilution factor, The diluting solution was inoculated into the SPF (specific pathogen free) eggs of 9-10 days of age by ureteral cavity path, respectively, and observed for 7 days to determine the time of death of the chicks. Depending on the mortality of the chicks, they died before 60 hours, died between 60 and 90 hours, and died after 90 hours, respectively. They are classified as velogenic, mesogenic, and lentogenic. It was. The results are shown in Table 1 below.

　 바이러스 주Virus note 결과(시간)Result (hours) 실시예 1Example 1 CBU2179CBU2179 167167 실시예 2Example 2 CBU2249CBU2249 168168 실시예 3Example 3 CBU2374CBU2374 165165 비교예 1Comparative Example 1 VG/GAVG / GA 140a 140 a 비교예 2Comparative Example 2 B-1B-1 120b 120 b

a, b 기존의 측정결과를 참고하였다.
 a, b The existing measurement results are referenced.

CBU2179의 경우 166.8시간, CBU2249는 168시간, CBU2374는 165시간으로 저병원성을 가지고 있음을 확인할 수 있었고, VG/GA, B-1 주보다 저병원성임을 확인하였다. In the case of CBU2179, 166.8 hours, CBU2249 was 168 hours, and CBU2374 was 165 hours, and it was confirmed that they were less pathogenic than VG / GA and B-1.

ICPI를 확인하기 위하여, HA titer가 24이상인 Seed 바이러스를 멸균 등장액을 이용하여 1/10로 희석하고 SPF 계란에서 부화한지 24시간~40시간 된 10마리의 병아리에 각각 뇌내로 0.05ml을 접종하고 하루에 한 번 8일간 관찰하였다. 매 24시간 관찰기간 동안 정상인 개체는 0점, 아픈 개체는 1점, 죽은 개체는 2점으로 하고 죽은 개체는 남은 관찰기간 동안 2점으로 계산하고, 살아있지만 음수나 사료섭취가 불가능한 개체는 안락사시키고 2점으로 인정하였다. 8일 후 각 개체별 관찰기간을 통합하여 평균을 산출한 결과 Seed 바이러스의 뇌내 접종 독성지수는 0.14로 확인되었다. 참고적으로 대부분의 뉴캣슬병 백신주의 뇌내 접종 독성 지수는 0.0?0.4 정도이며, B1은 0.20, VG/GA는 0.03으로 알려져 있다
To confirm ICPI, the Seed virus with HA titer greater than 2 4 was diluted 1/10 with sterile isotonic solution and inoculated with 0.05 ml into the brain of 10 chicks, 24 to 40 hours after hatching from SPF eggs. Observations were made for 8 days once a day. For every 24 hours of observation, normal subjects scored 0 points, sick individuals scored 1 point, dead individuals scored 2 points, and dead individuals scored 2 points for the remainder of the observation period. 2 points were recognized. After 8 days, the mean of the observation period for each individual was calculated and the average inoculation toxicity index of Seed virus was 0.14. For reference, the inoculation toxicity index of most Newcastle disease vaccines ranges from 0.0 to 0.4, B1 is 0.20, and VG / GA is 0.03.

또한, 호흡기계에 대한 병원성을 관찰하기 위해, 3주령 SPF(specific pathogen free) 닭에 CBU2179, CBU2249, CBU2374, VG/GA, B-1를 접종한 다음 5dpi에 기관을 약 1~2mm 간격으로 횡절단하여 내강의 섬모의 운동성을 관찰하였다. 그 결과를 표 2에 나타내었다. In addition, in order to observe pathogenicity to the respiratory system, three-week-old SPF (specific pathogen free) chickens were inoculated with CBU2179, CBU2249, CBU2374, VG / GA, and B-1, and the trachea was traversed at about 1 to 2 mm at 5 dpi. Cutting was performed to observe the motility of the lumen of the lumen. The results are shown in Table 2.

　 접종두수Inoculation head 바이러스A Virus A 항체가 평균(Geometric mean of HI titer)B
(접종 후 일 수)Antibody average of HI titer B
(Days after vaccination) 평균 섬모운동성인덱스(Average Ciliostasis Index)C Average Ciliostasis Index C 방어율(%)
(생존수/도전감염수)D % ERA
(Survival water / conductive infected water) D 55 1010 1414 1One 3434 CBU2179CBU2179 3.4±0.843.4 ± 0.84 4.1±0.744.1 ± 0.74 5.0±0.945.0 ± 0.94 4.5±3.844.5 ± 3.84 100 (11/11)100 (11/11) 22 3434 CBU2249CBU2249 1.6±0.71.6 ± 0.7 4.1±1.24.1 ± 1.2 4.7±1.04.7 ± 1.0 7.3±6.627.3 ± 6.62 100 (11/11)100 (11/11) 33 3434 CBU2374CBU2374 2.0±0.82.0 ± 0.8 4.4±1.24.4 ± 1.2 5.5±0.75.5 ± 0.7 6.5±6.136.5 ± 6.13 100 (11/11)100 (11/11) 44 3434 VG/GAVG / GA 1.8±0.631.8 ± 0.63 4.5±0.714.5 ± 0.71 5.2±0.795.2 ± 0.79 7.8±5.627.8 ± 5.62 90.9 (10/11)90.9 (10/11) 55 3434 B-1B-1 2.7±0.672.7 ± 0.67 6.5±0.716.5 ± 0.71 6.7±0.876.7 ± 0.87 10.0±8.7410.0 ± 8.74 100 (11/11)100 (11/11) 66 3434 (-) control(-) control 00 00 0 d 0 d 1.8±1.031.8 ± 1.03 0 (0/11)0 (0/11)

A 3주령 닭은 개체당 106 EID50로 점안/경구 경로로 백신화하였다. A 3 week-old chicken is 10 6 EID 50 per individual. Vaccination was by eye / oral route.

B 접종 후 매일 혈청 샘플링을 위해 각 그룹당 10마리씩 선별되었다. B 10 animals in each group for daily serum sampling after inoculation Selected.

C. 접종 5일 후 10마리를 안락사시키고　기관 섬모를 현미경으로 관찰하였다. C. Five animals were euthanized 5 days after inoculation and organ cilia were observed under a microscope.

D 접종 2주 후, 점안 경로로 KJW 주를 치사량인 마리당 105.5EID50로 도전감염시켰고 2주간 관찰하였다.
D Two weeks after inoculation, KJW was challenged with lethal dose of 10 5.5 EID 50 per horse and observed for two weeks.

관찰결과 CBU2179, CBU2249 및 CBU2374를 접종한 닭의 기관 섬모 운동성이 VG/GA나 B-1을 접종한 닭의 그것에 비해 같거나 좋은 것으로 확인되었다.
Observations showed that the organ cilia motility of chickens inoculated with CBU2179, CBU2249 and CBU2374 was the same or better than that of chickens inoculated with VG / GA or B-1.

실시예4Example 4 : : 역가Titer 비교 실험 Comparative experiment

CBU2179, CBU2249 및 CBU2374와 종래 생백신 균주의 역가를 비교하기 위해, 백신을 접종한 닭의 혈청 HI 역가를 측정하는 방법과 백신 후 강독주 접종 후 방어능으로 역가를 측정하였다. 상기 표 2에 나타난 바와 같이, CBU2179를 접종한 경우, 기존의 백신주와 비슷하게 역가가 형성되었으며 방어능에 있어서도 기존 백신주와 같은 수준으로 확인되었고, CBU2249 및 CBU2374의 경우에도 유사한 수준으로 확인되었다.
To compare the titers of CBU2179, CBU2249 and CBU2374 with conventional live vaccine strains, titers were measured by the method of measuring serum HI titers of vaccinated chickens and the protective ability after vaccination with vaccination. As shown in Table 2, when inoculated with CBU2179, a titer was formed similarly to the existing vaccine strain, and the level of protection was confirmed to be the same as the existing vaccine strain, and similar levels were also confirmed for the CBU2249 and CBU2374.

실시예5Example 5 : 방어율 및 지속성 비교 실험: ERA and persistence comparison experiment

CBU2179 와 종래 생백신 균주의 방어율을 비교하기 위해, 접종 후 14일에 국내 고병원성 분리주인 KJW 주를 105.5 EID50으로 점안 접종하였다. 상기 표 2에 나타난 바와 같이, 대조군은 모두 폐사한 반면 CBU2179 접종군은 100%의 방어율을 나타내었고, CBU2249 및 CBU2374의 경우 또한, 유사하게 나타내었다.
To compare the protection rates of CBU2179 and conventional live vaccine strains, KJW strain, a Korean highly pathogenic isolate, was inoculated with 10 5.5 EID 50 at 14 days after inoculation. As shown in Table 2, the control group all died, whereas the CBU2179 inoculation group showed a 100% protection rate, and similarly for CBU2249 and CBU2374.

또한 CBU2179 와 종래 생백신 균주의 친화성 및 지속성을 비교하기 위해, 3주령 닭에 접종한 후 조직에 대한 친화성과 지속성을 HA 유무로서 평가한 결과를 표 3에 나타내었다. In addition, in order to compare the affinity and persistence of CBU2179 and conventional live vaccine strains, the results of evaluating the affinity and persistence for tissues after HA inoculation in 3 weeks old chicken as HA is shown in Table 3.

　 　
바이러스
　
virus
Tissues sampled at days post inoculationTissues sampled at days post inoculation 기관(Trachea)Trachea 십이지장(Duodenum)Duodenum 맹장편도(Ceacal tonsil)Cecal tonsil 33 55 1010 33 55 1010 33 55 1010 실시예Example VI072179VI072179 3/33/3 1/31/3 0/30/3 2/32/3 3/33/3 2/32/3 2/32/3 3/33/3 1/31/3 비교예1Comparative Example 1 VG/GAVG / GA 3/33/3 2/32/3 0/30/3 2/32/3 3/33/3 0/30/3 2/32/3 1/31/3 0/30/3 비교예2Comparative Example 2 B1B1 3/33/3 3/33/3 0/30/3 1/31/3 1/31/3 0/30/3 3/33/3 2/32/3 0/30/3 대조군Control group (-) control(-) control 0/30/3 0/30/3 0/30/3 0/30/3 0/30/3 0/30/3 0/30/3 0/30/3 0/30/3

A 21일째 점안/경구 경로로 마리당 106 EID50씩 각각 접종하였다. A 21 days each was inoculated with 10 6 EID 50 per eye via the eye / oral route.

B 설계된 날짜에 조직을 채취하여 무균술로 균질화하였다. B Tissues were harvested at the designed date and homogenized by aseptic technique.

상기 표 3에 나타난 바와 같이, CBU2179는 기관과 십이지장 맹장편도에서 모두 골고루 오래 지속되는 것을 확인할 수 있었다.　CBU2249 및 CBU2374에서도 유사한 결과를 확인할 수 있었다.
As shown in Table 3, CBU2179 was confirmed to last evenly in both tracheal and duodenal tonsils. Similar results were found in CBU2249 and CBU2374.

한국생명공학연구원Korea Research Institute of Bioscience and Biotechnology KCTC11530BPKCTC11530BP 2009072120090721 한국생명공학연구원Korea Research Institute of Bioscience and Biotechnology KCTC11111BPKCTC11111BP 2011082920110829 한국생명공학연구원Korea Research Institute of Bioscience and Biotechnology KCTC22222BPKCTC22222BP 2011082920110829

<110> ChoongAng Vaccine Lab. Chungbuk National University Industry Academic Cooperation Foundation <120> A LENTOGENIC NEWCASTLE DISEASE VIRUS AND VACCINE CONTAINING THE SAME <130> IPDC-37843 <150> KR 2010/085684 <151> 2010-09-01 <160> 12 <170> KopatentIn 2.0 <210> 1 <211> 553 <212> PRT <213> Newcastle disease virus <400> 1 Met Gly Ser Arg Ser Ser Thr Arg Ile Pro Val Pro Leu Met Leu Thr 1 5 10 15 Val Arg Val Ala Leu Ala Leu Cys Cys Val Arg Leu Thr Ser Ser Leu 20 25 30 Asp Gly Arg Pro Leu Ala Ala Ala Gly Ile Val Val Thr Gly Asp Lys 35 40 45 Ala Val Asn Ile Tyr Thr Ser Ser Gln Thr Gly Ser Ile Ile Val Lys 50 55 60 Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Ala Cys Ala Lys Ala Pro 65 70 75 80 Leu Glu Ala Tyr Asn Arg Thr Leu Thr Thr Leu Leu Thr Pro Leu Gly 85 90 95 Asp Ser Ile Arg Arg Ile Gln Glu Ser Val Thr Thr Ser Gly Gly Gly 100 105 110 Lys Gln Gly Arg Leu Ile Gly Ala Ile Ile Gly Gly Ala Ala Leu Gly 115 120 125 Val Ala Thr Ala Ala Gln Ile Thr Ala Ala Ser Ala Leu Ile Gln Ala 130 135 140 Asn Gln Asn Ala Ala Asn Ile Leu Arg Leu Lys Glu Ser Ile Ala Ala 145 150 155 160 Thr Asn Glu Ala Val His Glu Val Thr Asp Gly Leu Ser Gln Leu Ala 165 170 175 Val Ala Val Gly Lys Met Gln Gln Phe Val Asn Asp Gln Phe Asn Lys 180 185 190 Thr Ala Gln Glu Leu Asp Cys Ile Lys Ile Thr Gln Gln Val Gly Val 195 200 205 Glu Leu Asn Leu Tyr Leu Thr Glu Leu Thr Thr Val Phe Gly Pro Gln 210 215 220 Ile Thr Ser Pro Ala Leu Thr Gln Leu Thr Ile Gln Ala Leu Tyr Asn 225 230 235 240 Leu Ala Gly Gly Asn Met Asp Tyr Leu Leu Thr Lys Leu Gly Val Gly 245 250 255 Asn Asn Gln Leu Ser Ser Leu Ile Gly Ser Gly Leu Ile Thr Gly Asn 260 265 270 Pro Ile Leu Tyr Asp Ser Gln Thr Gln Leu Leu Gly Ile Gln Val Thr 275 280 285 Leu Pro Ser Val Gly Asn Leu Asn Asn Met Arg Ala Thr Tyr Leu Glu 290 295 300 Thr Leu Ser Val Ser Thr Thr Lys Gly Phe Ala Ser Ala Leu Val Pro 305 310 315 320 Lys Val Val Thr Gln Val Gly Ser Val Ile Glu Glu Leu Asp Thr Ser 325 330 335 Tyr Cys Ile Glu Thr Asp Leu Asp Leu Tyr Cys Thr Arg Ile Val Thr 340 345 350 Phe Pro Met Ser Pro Gly Ile Tyr Ser Cys Leu Ser Gly Asn Thr Ser 355 360 365 Ala Cys Met Tyr Ser Lys Thr Glu Gly Ala Leu Thr Thr Pro Tyr Met 370 375 380 Thr Leu Lys Gly Ser Val Ile Ala Asn Cys Lys Met Thr Thr Cys Arg 385 390 395 400 Cys Ala Asp Pro Pro Gly Ile Ile Ser Gln Asn Tyr Gly Glu Ala Val 405 410 415 Ser Leu Ile Asp Arg Gln Ser Cys Asn Ile Leu Ser Leu Asp Gly Ile 420 425 430 Thr Leu Arg Leu Ser Gly Glu Phe Asp Ala Thr Tyr Gln Lys Asn Ile 435 440 445 Ser Ile Gln Asp Ser Gln Val Ile Val Thr Gly Asn Leu Asp Ile Ser 450 455 460 Thr Glu Leu Gly Asn Val Asn Asn Ser Ile Ser Asn Ala Leu Asp Lys 465 470 475 480 Leu Glu Glu Ser Asn Ser Lys Leu Asp Lys Val Asn Val Lys Leu Thr 485 490 495 Ser Thr Ser Ala Leu Ile Thr Tyr Ile Val Leu Thr Ala Ile Ser Leu 500 505 510 Val Cys Gly Ile Leu Ser Leu Val Leu Ala Cys Tyr Leu Met Tyr Lys 515 520 525 Gln Lys Ala Gln Gln Lys Thr Leu Leu Trp Leu Gly Asn Asn Thr Leu 530 535 540 Asp Gln Met Arg Ala Thr Thr Lys Met 545 550 <210> 2 <211> 553 <212> PRT <213> Newcastle disease virus <400> 2 Met Gly Ser Arg Ser Ser Thr Arg Ile Pro Val Pro Leu Met Leu Thr 1 5 10 15 Val Arg Val Ala Leu Ala Leu Cys Cys Val Arg Leu Thr Ser Ser Leu 20 25 30 Asp Gly Arg Pro Leu Ala Ala Ala Gly Ile Val Val Thr Gly Asp Lys 35 40 45 Ala Val Asn Ile Tyr Thr Ser Ser Gln Thr Gly Ser Ile Ile Val Lys 50 55 60 Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Ala Cys Ala Lys Ala Pro 65 70 75 80 Leu Glu Ala Tyr Asn Arg Thr Leu Thr Thr Leu Leu Thr Pro Leu Gly 85 90 95 Asp Ser Ile Arg Arg Ile Gln Glu Ser Val Thr Thr Ser Gly Gly Gly 100 105 110 Lys Gln Gly Arg Leu Ile Gly Ala Ile Ile Gly Gly Ala Ala Leu Gly 115 120 125 Val Ala Thr Ala Ala Gln Ile Thr Ala Ala Ser Ala Leu Ile Gln Ala 130 135 140 Asn Gln Asn Ala Ala Asn Ile Leu Arg Leu Lys Glu Ser Ile Ala Ala 145 150 155 160 Thr Asn Glu Ala Val His Glu Val Thr Asp Gly Leu Ser Gln Leu Ala 165 170 175 Val Ala Val Gly Lys Met Gln Gln Phe Val Asn Asp Gln Phe Asn Lys 180 185 190 Thr Ala Gln Glu Leu Asp Cys Ile Lys Ile Thr Gln Gln Val Gly Val 195 200 205 Glu Leu Asn Leu Tyr Leu Thr Glu Leu Thr Thr Val Phe Gly Pro Gln 210 215 220 Ile Thr Ser Pro Ala Leu Thr Gln Leu Thr Ile Gln Ala Leu Tyr Asn 225 230 235 240 Leu Ala Gly Gly Asn Met Asp Tyr Leu Leu Thr Lys Leu Gly Val Gly 245 250 255 Asn Asn Gln Leu Ser Ser Leu Ile Gly Ser Gly Leu Ile Thr Gly Asn 260 265 270 Pro Ile Leu Tyr Asp Ser Gln Thr Gln Leu Leu Gly Ile Gln Val Thr 275 280 285 Leu Pro Ser Val Gly Asn Leu Asn Asn Met Arg Ala Thr Tyr Leu Glu 290 295 300 Thr Leu Ser Val Ser Thr Thr Lys Gly Phe Ala Ser Ala Leu Val Pro 305 310 315 320 Lys Val Val Thr Gln Val Gly Ser Val Ile Glu Glu Leu Asp Thr Ser 325 330 335 Tyr Cys Ile Glu Thr Asp Leu Asp Leu Tyr Cys Thr Arg Ile Val Thr 340 345 350 Phe Pro Met Ser Pro Gly Ile Tyr Ser Cys Leu Ser Gly Asn Thr Ser 355 360 365 Ala Cys Met Tyr Ser Lys Thr Glu Gly Ala Leu Thr Thr Pro Tyr Met 370 375 380 Thr Leu Lys Gly Ser Val Ile Ala Asn Cys Lys Met Thr Thr Cys Arg 385 390 395 400 Cys Ala Asp Pro Pro Gly Ile Ile Ser Gln Asn Tyr Gly Glu Ala Val 405 410 415 Ser Leu Ile Asp Arg Gln Ser Cys Asn Ile Leu Ser Leu Asp Gly Ile 420 425 430 Thr Leu Arg Leu Ser Gly Glu Phe Asp Ala Thr Tyr Gln Lys Asn Ile 435 440 445 Ser Ile Gln Asp Ser Gln Val Ile Val Thr Gly Asn Leu Asp Ile Ser 450 455 460 Thr Glu Leu Gly Asn Val Asn Asn Ser Ile Ser Asn Ala Leu Asp Lys 465 470 475 480 Leu Glu Glu Ser Asn Ser Lys Leu Asp Lys Val Asn Val Lys Leu Thr 485 490 495 Ser Thr Ser Ala Leu Ile Thr Tyr Ile Val Leu Thr Val Ile Ser Leu 500 505 510 Val Cys Gly Ile Leu Ser Leu Val Leu Ala Cys Tyr Leu Met Tyr Lys 515 520 525 Gln Lys Ala Gln Gln Lys Thr Leu Leu Trp Leu Gly Asn Asn Thr Leu 530 535 540 Asp Gln Met Arg Ala Thr Thr Lys Met 545 550 <210> 3 <211> 553 <212> PRT <213> Newcastle disease virus <400> 3 Met Gly Ser Arg Ser Ser Thr Arg Ile Pro Val Pro Leu Met Leu Thr 1 5 10 15 Val Arg Val Ala Leu Ala Leu Ser Cys Val Arg Leu Thr Ser Ser Leu 20 25 30 Asp Gly Arg Pro Leu Ala Ala Ala Gly Ile Val Val Thr Gly Asp Lys 35 40 45 Ala Val Asn Ile Tyr Thr Ser Ser Gln Thr Gly Ser Ile Ile Val Lys 50 55 60 Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Ala Cys Ala Lys Ala Pro 65 70 75 80 Leu Glu Ala Tyr Asn Arg Thr Leu Thr Thr Leu Leu Thr Pro Leu Gly 85 90 95 Asp Ser Ile Arg Arg Ile Gln Glu Ser Val Thr Thr Ser Gly Gly Gly 100 105 110 Lys Gln Gly Arg Leu Ile Gly Ala Ile Ile Gly Gly Ala Ala Leu Gly 115 120 125 Val Ala Thr Ala Ala Gln Ile Thr Ala Ala Ser Ala Leu Ile Gln Ala 130 135 140 Asn Gln Asn Ala Ala Asn Ile Leu Arg Leu Lys Glu Ser Ile Ala Ala 145 150 155 160 Thr Asn Glu Ala Val His Glu Val Thr Asp Gly Leu Ser Gln Leu Ala 165 170 175 Val Ala Val Gly Lys Met Gln Gln Phe Val Asn Asp Gln Phe Asn Lys 180 185 190 Thr Ala Gln Glu Leu Asp Cys Ile Lys Ile Thr Gln Gln Val Gly Val 195 200 205 Glu Leu Asn Leu Tyr Leu Thr Glu Leu Thr Thr Val Phe Gly Pro Gln 210 215 220 Ile Thr Ser Pro Ala Leu Thr Gln Leu Thr Ile Gln Ala Leu Tyr Asn 225 230 235 240 Leu Ala Gly Gly Asn Met Asp Tyr Leu Leu Thr Lys Leu Gly Val Gly 245 250 255 Asn Asn Gln Leu Ser Ser Leu Ile Ser Ser Gly Leu Ile Thr Gly Asn 260 265 270 Pro Ile Leu Tyr Asp Ser Gln Thr Gln Leu Leu Gly Ile Gln Val Thr 275 280 285 Leu Pro Ser Val Gly Asn Leu Asn Asn Met Arg Ala Thr Tyr Leu Glu 290 295 300 Thr Leu Ser Val Ser Thr Thr Lys Gly Phe Ala Ser Ala Leu Val Pro 305 310 315 320 Lys Val Val Thr Gln Val Gly Ser Val Ile Glu Glu Leu Asp Thr Ser 325 330 335 Tyr Cys Ile Glu Thr Asp Leu Asp Leu Tyr Cys Thr Arg Ile Val Thr 340 345 350 Phe Pro Met Ser Pro Gly Ile Tyr Ser Cys Leu Ser Gly Asn Thr Ser 355 360 365 Ala Cys Met Tyr Ser Lys Thr Glu Gly Ala Leu Thr Thr Pro Tyr Met 370 375 380 Thr Leu Lys Gly Ser Val Ile Ala Asn Cys Lys Met Thr Thr Cys Arg 385 390 395 400 Cys Ala Asp Pro Pro Gly Ile Ile Ser Gln Asn Tyr Gly Glu Ala Val 405 410 415 Ser Leu Ile Asp Lys Gln Ser Cys Asn Ile Leu Ser Leu Asp Gly Ile 420 425 430 Thr Leu Arg Leu Ser Gly Glu Phe Asp Ala Thr Tyr Gln Lys Asn Ile 435 440 445 Ser Ile Gln Asp Ser Gln Val Ile Val Thr Gly Asn Leu Asp Ile Ser 450 455 460 Thr Glu Leu Gly Asn Val Asn Asn Ser Ile Ser Asn Ala Leu Asp Lys 465 470 475 480 Leu Glu Glu Ser Asn Ser Lys Leu Asp Lys Val Asn Val Lys Leu Thr 485 490 495 Ser Thr Ser Ala Leu Ile Thr Tyr Ile Val Leu Thr Val Ile Ser Leu 500 505 510 Val Cys Gly Ile Leu Ser Leu Val Leu Ala Cys Tyr Leu Met Tyr Lys 515 520 525 Gln Lys Ala Gln Gln Lys Thr Leu Leu Trp Leu Gly Asn Asn Thr Leu 530 535 540 Asp Gln Met Arg Ala Thr Thr Lys Ile 545 550 <210> 4 <211> 616 <212> PRT <213> Newcastle disease virus <400> 4 Met Asp Arg Ala Val Ser Gln Val Ala Leu Glu Asn Asp Glu Arg Glu 1 5 10 15 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Ile Leu Leu Leu 20 25 30 Thr Val Val Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr Ser Met 35 40 45 Glu Ala Ser Thr Pro Ser Asp Leu Val Gly Ile Pro Thr Ala Ile Ser 50 55 60 Arg Ala Glu Glu Arg Ile Thr Ser Ala Leu Gly Ser Asn Gln Asp Val 65 70 75 80 Val Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu 85 90 95 Leu Asn Thr Glu Ser Thr Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr 100 105 110 Gln Ile Asn Arg Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Ile His 115 120 125 Asp Pro Asp Tyr Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp 130 135 140 Ala Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Phe Gln Glu His Leu 145 150 155 160 Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro 165 170 175 Ser Phe Asp Met Ser Ala Thr His Tyr Cys Tyr Thr His Asn Val Ile 180 185 190 Leu Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu 195 200 205 Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu 210 215 220 Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val 225 230 235 240 Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu 245 250 255 Thr Glu Lys Glu Asp Tyr Asn Ser Ala Ile Pro Thr Ser Met Val His 260 265 270 Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Val 275 280 285 Thr Thr Leu Phe Gly Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly 290 295 300 Gly Ser Phe Ile Asp Asn Arg Val Trp Phe Pro Val Tyr Gly Gly Leu 305 310 315 320 Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile 325 330 335 Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile 340 345 350 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg 355 360 365 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Glu 370 375 380 Asp Pro Val Leu Thr Ile Pro Pro Asn Thr Ile Thr Leu Met Gly Ala 385 390 395 400 Glu Gly Arg Val Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg 405 410 415 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Ser 420 425 430 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr 435 440 445 Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser 450 455 460 Cys Val Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Val Phe Tyr Arg 465 470 475 480 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Glu Gln 485 490 495 Ala Arg Leu Asn Pro Val Ser Ala Val Phe Asp Ser Ile Ser Arg Ser 500 505 510 Arg Ile Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr 515 520 525 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser 530 535 540 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro 545 550 555 560 Leu Leu Val Glu Ile Leu Lys Asp Asp Gly Val Arg Glu Ala Arg Ser 565 570 575 Gly Arg Leu Ser Gln Leu Gln Glu Gly Trp Lys Asp Asp Ile Val Ser 580 585 590 Pro Ile Phe Cys Asp Thr Lys Asn Gln Thr Glu Tyr Arg Arg Glu Leu 595 600 605 Glu Ser Tyr Ala Ala Ser Trp Pro 610 615 <210> 5 <211> 616 <212> PRT <213> Newcastle disease virus <400> 5 Met Asp Arg Ala Val Ser Gln Val Ala Leu Glu Asn Asp Glu Arg Glu 1 5 10 15 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Ile Leu Leu Leu 20 25 30 Thr Val Val Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr Ser Met 35 40 45 Glu Ala Ser Thr Pro Ser Asp Leu Val Gly Ile Pro Thr Ala Ile Ser 50 55 60 Arg Ala Glu Glu Arg Ile Thr Ser Ala Leu Gly Ser Asn Gln Asp Val 65 70 75 80 Val Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu 85 90 95 Leu Asn Thr Glu Ser Thr Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr 100 105 110 Gln Ile Asn Gly Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Ile His 115 120 125 Asp Pro Asp Tyr Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp 130 135 140 Ala Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Phe Gln Glu His Leu 145 150 155 160 Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro 165 170 175 Ser Phe Asp Met Ser Ala Thr His Tyr Cys Tyr Thr His Asn Val Ile 180 185 190 Leu Ser Gly Cys Arg Asp His Ser His Ser Tyr Gln Tyr Leu Ala Leu 195 200 205 Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu 210 215 220 Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val 225 230 235 240 Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu 245 250 255 Thr Glu Lys Glu Asp Tyr Asn Ser Ala Ile Pro Thr Ser Met Val His 260 265 270 Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Val 275 280 285 Thr Thr Leu Phe Gly Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly 290 295 300 Gly Ser Phe Ile Asp Asn Arg Val Trp Phe Pro Val Tyr Gly Gly Leu 305 310 315 320 Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile 325 330 335 Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile 340 345 350 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg 355 360 365 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Glu 370 375 380 Asp Pro Val Leu Thr Ile Pro Pro Asn Thr Ile Thr Leu Met Gly Ala 385 390 395 400 Glu Gly Arg Val Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg 405 410 415 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Ser 420 425 430 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr 435 440 445 Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser 450 455 460 Cys Val Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Val Phe Tyr Arg 465 470 475 480 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Glu Gln 485 490 495 Ala Arg Leu Asn Pro Val Ser Ala Val Phe Asp Ser Ile Ser Arg Ser 500 505 510 Arg Ile Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr 515 520 525 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser 530 535 540 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro 545 550 555 560 Leu Leu Val Glu Ile Leu Lys Asp Asp Gly Val Arg Glu Ala Arg Ser 565 570 575 Gly Arg Leu Ser Gln Leu Gln Glu Gly Trp Lys Asp Asp Ile Val Ser 580 585 590 Pro Ile Phe Cys Asp Thr Lys Asn Gln Thr Glu Tyr Arg Arg Glu Leu 595 600 605 Glu Ser Tyr Ala Ala Ser Trp Pro 610 615 <210> 6 <211> 616 <212> PRT <213> Newcastle disease virus <400> 6 Met Asp Arg Ala Val Ser Gln Val Ala Leu Glu Asn Asp Glu Arg Glu 1 5 10 15 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Ile Leu Leu Leu 20 25 30 Thr Val Val Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr Ser Met 35 40 45 Glu Ala Ser Thr Pro Ser Asp Leu Ile Gly Ile Pro Thr Ala Ile Ser 50 55 60 Arg Ala Glu Glu Arg Ile Thr Ser Ala Leu Gly Ser Asn Gln Asp Val 65 70 75 80 Val Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu 85 90 95 Leu Asn Thr Glu Ser Thr Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr 100 105 110 Gln Ile Asn Gly Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Ile His 115 120 125 Asp Pro Asp Tyr Ile Glu Gly Ile Gly Lys Glu Leu Ile Val Asp Asp 130 135 140 Ala Ser Asp Val Ile Ser Phe Tyr Pro Ser Ala Phe Gln Glu His Leu 145 150 155 160 Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro 165 170 175 Ser Phe Asp Met Ser Ala Thr His Tyr Cys Tyr Thr His Asn Val Ile 180 185 190 Leu Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu 195 200 205 Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu 210 215 220 Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val 225 230 235 240 Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu 245 250 255 Thr Glu Glu Glu Asp Tyr Asn Ser Ala Ile Pro Thr Ser Met Val His 260 265 270 Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Val 275 280 285 Thr Thr Leu Phe Gly Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly 290 295 300 Gly Ser Phe Ile Asp Asn Arg Val Trp Phe Pro Val Tyr Gly Gly Leu 305 310 315 320 Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile 325 330 335 Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile 340 345 350 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg 355 360 365 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Glu 370 375 380 Asp Pro Val Leu Thr Val Pro Pro Asn Thr Val Thr Leu Met Gly Ala 385 390 395 400 Glu Gly Arg Val Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg 405 410 415 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Ser 420 425 430 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr 435 440 445 Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser 450 455 460 Cys Val Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Val Phe Tyr Arg 465 470 475 480 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Glu Gln 485 490 495 Ala Arg Leu Asn Pro Val Ser Ala Val Phe Asp Ser Ile Ser Arg Ser 500 505 510 Arg Ile Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr 515 520 525 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser 530 535 540 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro 545 550 555 560 Leu Leu Val Glu Ile Leu Lys Asp Asp Gly Val Arg Glu Ala Arg Ser 565 570 575 Gly Arg Leu Ser Gln Leu Gln Glu Gly Trp Lys Asp Asp Ile Val Ser 580 585 590 Pro Ile Phe Cys Asp Ile Lys Asn Gln Thr Glu Tyr Arg His Glu Ile 595 600 605 Glu Ser Tyr Ala Ala Ser Trp Pro 610 615 <210> 7 <211> 1662 <212> DNA <213> Newcastle disease virus <400> 7 atgggctcca gatcttctac caggatccca gtacctctga tgctgactgt tcgggtcgcg 60 ctggcattgt gttgcgtccg tctgacaagc tcccttgatg gcaggcctct tgcagctgca 120 gggattgtgg taacaggaga caaagcagtc aacatataca cctcatccca gacagggtcg 180 atcatagtca agttactccc caatatgccc aaggacaaag aggcatgtgc aaaagccccg 240 ttggaggcat acaacaggac attgactact ctgctcaccc cccttggtga ttctatccgt 300 aggatacaag agtccgtgac tacatctgga ggagggaaac agggacgcct tataggcgct 360 attatcggtg gtgcggctct cggggttgca accgctgcac agataacagc agcctcggct 420 ctgatacagg ccaaccaaaa tgctgccaac attctccgac ttaaagagag cattgctgca 480 accaatgagg ctgtgcacga agtcactgac ggattatcac aactggccgt ggcagtcggg 540 aagatgcaac aatttgttaa tgaccagttt aataaaacag ctcaggaatt ggactgtata 600 aaaattacac agcaggttgg tgtagaactc aacttgtacc taactgaatt gactacagta 660 ttcgggccac aaatcacttc ccctgcccta acccagctga ccatccaggc actttataat 720 ctagctggtg ggaatatgga ttacttgttg acaaagttag gtgtagggaa caaccaactt 780 agctcattaa ttggtagcgg cctgatcacc ggcaatccta tcttgtacga ctcacagact 840 cagctcttgg gtatacaggt aaccctaccc tcagtcggga acctgaataa tatgcgtgcc 900 acctacttgg aaactttgtc tgtaagtaca accaaaggat ttgcctcagc acttgtccca 960 aaggtggtga cacaagtcgg ttccgtgata gaagaacttg acacctcata ctgcatagag 1020 accgatttag atttatattg tacaagaata gtgacattcc ctatgtctcc tggtatttac 1080 tcctgtttga gcggcaatac atcggcttgt atgtattcga agactgaggg tgcactcact 1140 acaccgtaca tgactctcaa aggctcggtt attgccaact gtaagatgac aacatgtaga 1200 tgtgcagacc ccccgggtat catatcgcag aattatggag aagctgtgtc tctaatagat 1260 aggcaatcat gcaatatctt atccttggac gggataactt tgaggctcag tggggaattt 1320 gatgcaactt atcaaaagaa tatctcaata caagattctc aagtaatcgt gacaggcaat 1380 ctcgatatct caactgagct tgggaatgtt aacaactcga taagtaatgc tctagataag 1440 ttagaggaaa gcaacagcaa actagacaag gtcaatgtca aactgaccag cacatctgcc 1500 ctcatcacct atattgttct aactgccata tctcttgttt gcggcatact tagcttggtt 1560 ctagcgtgct acctgatgta caagcaaaag gcgcaacaga agactctgtt atggcttggg 1620 aataataccc tggaccaaat gagggccact acaaaaatgt ga 1662 <210> 8 <211> 1662 <212> DNA <213> Newcastle disease virus <400> 8 atgggctcca gatcttctac caggatccca gtacctctga tgctgactgt tcgggtcgcg 60 ctggcactgt gttgcgtccg tctgacaagc tcccttgatg gcaggcctct tgcagctgca 120 gggattgtgg taacaggaga caaagcagtc aacatataca cctcatccca gacagggtcg 180 atcatagtca agttactccc caatatgccc aaggacaaag aggcatgtgc aaaagccccg 240 ttagaggcgt acaacaggac attgactact ctgctcaccc cccttggtga ttctatccgt 300 aggatacaag agtccgtgac tacatctgga ggagggaaac agggacgcct tataggcgct 360 attatcggtg gtgcggctct cggggttgca accgctgcac agataacagc agcctcggct 420 ctgatacaag ccaaccaaaa tgctgccaac attctccgac ttaaagagag cattgctgca 480 accaatgagg ctgtgcacga agtcactgac ggattatcac aactagccgt ggcagtcggg 540 aagatgcaac aatttgttaa tgaccagttt aataaaacag ctcaggaatt ggactgtata 600 aaaattacac agcaggttgg tgtagaactc aacctgtacc taactgaatt gactacagta 660 ttcgggccac aaatcacttc ccctgcctta acccagctga ccatccaggc actttataat 720 ctagctggtg ggaatatgga ttacttgttg acaaagttag gtgtagggaa caaccaactt 780 agctcattaa ttggtagcgg cctgatcacc ggcaacccta tcttgtacga ctcacagact 840 cagctcttgg gtatacaggt aaccctaccc tcagtcggga acctgaataa tatgcgtgcc 900 acctacttgg aaaccttgtc tgtaagtaca accaaaggat ttgcctcagc acttgtccca 960 aaggtggtga cacaagtcgg ttccgtgata gaagaacttg acacctcata ctgcatagag 1020 accgatttag atttatattg tacaagaata gtgacattcc ctatgtctcc tggtatttac 1080 tcctgtttga gcggcaatac atcggcctgt atgtattcga agactgaggg cgcactcact 1140 acaccgtaca tgactctcaa aggctcggtt attgccaact gtaagatgac aacatgtaga 1200 tgtgcagacc ccccgggtat catatcgcag aattatggag aagctgtgtc tctaatagat 1260 aggcaatcat gcaatatctt atccttggac gggataactt tgaggctcag tggggaattt 1320 gatgcaactt atcaaaagaa catctcaata caagattctc aagtaatcgt gacaggcaat 1380 ctcgatatct caactgagct tgggaatgtt aacaactcga taagtaatgc tctagataag 1440 ttagaggaaa gcaacagcaa actagacaag gtcaatgtca aactgaccag cacatctgcc 1500 ctcatcacct atattgttct aactgtcata tctcttgttt gcggcatact tagcctggtt 1560 ctagcatgct acctgatgta caagcaaaag gcgcaacaga agaccttgtt atggcttggg 1620 aataataccc tggaccaaat gagggccact acaaaaatgt ga 1662 <210> 9 <211> 1662 <212> DNA <213> Newcastle disease virus <400> 9 atgggctcca gatcttctac caggatccca gtacctctga tgctgactgt ccgggtcgcg 60 ctggcactga gttgcgtccg tctgacaagc tcccttgatg gcaggcctct tgcagctgca 120 gggattgtgg taacaggaga caaagcagtc aacatataca cctcatccca gacagggtcg 180 atcatagtca agttactccc caatatgccc aaggacaaag aggcgtgtgc aaaagcccca 240 ttggaggcgt acaacaggac attgactact ctgctcaccc cccttggtga ttctatccgt 300 aggatacaag agtccgtgac tacatctgga ggagggaaac aggggcgcct tataggcgct 360 attatcggtg gtgcggctct cggggttgca accgctgcac agataacagc agcctcggct 420 ttgatacaag ccaaccaaaa tgctgctaac atcctccggc ttaaagagag cattgctgca 480 accaatgagg ctgtgcacga agtcactgac ggattatcac aactagccgt ggcagtcggg 540 aagatgcaac aatttgttaa tgaccagttt aacaaaacag ctcaggaatt ggactgtata 600 aaaattacac agcaggttgg tgtagaactc aacctgtacc taactgaatt gactacagta 660 ttcgggccac aaatcacctc ccctgctcta acccagctga ctatccaggc actttataat 720 ctagctggtg ggaatatgga ttacttgttg acaaagttag gtgtagggaa caaccaactc 780 agctcattaa ttagtagcgg cctgatcacc ggcaacccta tcctgtacga ctcacagact 840 cagctcctgg gtatacaggt aaccctaccc tcagttggga acctgaataa tatgcgtgcc 900 acctacctgg aaactttgtc tgtaagtaca accaaaggat ttgcctcagc acttgtccca 960 aaggtggtga cacaggtcgg ttccgtgata gaagaacttg acacctcata ctgtatagag 1020 accgatttag atctatattg tacaagaata gtgacattcc ctatgtctcc tggtatttac 1080 tcctgtttga gcggcaatac atcggcttgt atgtattcga agactgaggg cgcactcact 1140 acgccgtaca tgaccctcaa aggctcggtt attgccaact gtaagatgac aacatgtaga 1200 tgtgcagacc ccccgggtat catatcgcaa aattatggag aagctgtgtc tctaatagat 1260 aagcaatcgt gcaatatctt atccttggac gggataactt tgaggctcag tggggaattt 1320 gatgcaactt atcaaaagaa tatctcgata caagattctc aagtaatcgt gacaggcaat 1380 ctcgatatct cgactgagct tgggaatgtt aacaactcga taagtaatgc tctagataag 1440 ttagaggaaa gcaacagcaa actagacaag gtcaatgtca aactgaccag cacgtctgcc 1500 ctcatcacct acattgtttt aactgtcata tctcttgttt gcggtatact tagcctggtt 1560 ctagcatgct acctgatgta caagcaaaag gcgcaacaga agaccttgtt atggcttggg 1620 aataataccc tggaccagat gagggccact acgaaaatat ga 1662 <210> 10 <211> 1851 <212> DNA <213> Newcastle disease virus <400> 10 atggaccgcg cagttagcca agttgcgtta gagaatgatg agagagaggc aaagaataca 60 tggcgtttgg tattccggat cgcgatcctg cttctaacag ttgtgacctt agccatctct 120 gcagctgccc tcgcgtatag tatggaggct agcacaccta gcgaccttgt aggcataccg 180 actgcgatct ctagagcaga ggaaaggatt acatctgcac tcggttccaa ccaagatgta 240 gtagatagga tttataagca ggtggccctc gaatctccat tggcattgtt aaacaccgag 300 tctacaatta tgaatgcaat aacgtctctc tcttatcaga tcaatagggc tgcaaatagc 360 agcgggtgtg gggcgcctat tcatgatccg gattatatcg ggggaatagg taaagaactt 420 attgtagatg atgctagtga tgtcacttca ttctatccct ctgcgttcca agaacacctg 480 aactttatcc cggcgcctac tacaggatca ggttgcactc gaataccctc atttgacatg 540 agtgctaccc actattgtta tactcacaat gtgatattat ctggctgcag ggatcactcg 600 cactcacatc agtacctagc acttggcgtg cttcggacat ctgcaacagg gagggtattc 660 ttttctactc tgcgttccat taacctggat gacacccaaa accgaaagtc ttgcagtgtg 720 agtgcaactc ccttaggttg tgatatgctg tgctctaagg tcacagagac tgagaaagag 780 gattataact cagctatccc aacatcgatg gtacatggaa ggttagggtt cgacggccaa 840 taccatgaga aggacctaga tgtcacaaca ctattcggag actgggtggc gaattaccca 900 ggagtggggg gtggatcctt tattgacaac cgcgtgtggt tcccagttta tggagggcta 960 aaacccaact cgcctagtga cactgcacaa gaagggaaat atgtaatata caagcgatac 1020 aatgacacat gtccagatga gcaagattac cagattcgaa tggctaagtc ttcgtacaag 1080 cctgggcggt ttggtgggaa acgcgtgcaa caggccatct tatctatcaa agtgtctaca 1140 tccttgggcg aagacccggt gctgactata ccgcccaaca caatcacact catgggggct 1200 gaaggcagag ttctcacagt agggacatct cacttcttgt atcaacgagg gtcatcatac 1260 ttctctcctg ccttattata tcctatgaca gtcagcaaca aaacagccac tcttcatagt 1320 ccttatacat tcaacgcctt cactcgacca ggtagtgtcc cttgccaggc ttcagcaaga 1380 tgccctaatt catgtgttac cggggtctat actgatccat atcccttagt cttttatagg 1440 aaccatacct tgcgaggagt attcggaaca atgcttgatg atgaacaagc aagactcaac 1500 cctgtatctg cagtattcga cagcatatcc cgcagtcgca taacccgggt gagttcaagc 1560 agcaccaagg cagcatacac gacatcaacg tgttttaaag ttgtcaagac caataaaacc 1620 tattgtctca gcattgctga aatatccaac accctcttcg gggaattcag aattgtccct 1680 ttactagttg agattctcaa ggatgatggg gtcagagagg ccaggtctgg ccgattgagt 1740 cagctgcaag agggttggaa ggatgacatt gtatcaccta tcttttgtga cactaagaat 1800 caaactgaat accggcgtga gctcgagtct tatgctgcca gctggccata a 1851 <210> 11 <211> 1851 <212> DNA <213> Newcastle disease virus <400> 11 atggaccgcg cagttagcca agttgcgtta gagaatgatg agagagaggc aaagaataca 60 tggcgtttgg tattccggat cgcgatcctg cttctaacag ttgtgacctt agccatctct 120 gcagctgccc ttgcgtatag tatggaggct agcacaccta gcgaccttgt aggcataccg 180 actgcgatct ctagagcaga ggaaaggatt acatctgcac tcggttccaa ccaagatgta 240 gtagatagga tttataagca ggtggccctc gaatctccat tggcattgct aaacaccgag 300 tctacaatta tgaatgcaat aacgtctctc tcttatcaga tcaatggggc cgcaaatagc 360 agcgggtgtg gggcacctat tcatgatccg gattatatcg ggggaatagg taaagaactt 420 attgtagatg atgctagtga tgtcacatca ttctatccct ctgcgttcca agaacacctg 480 aactttatcc cggcgcctac tacaggatca ggttgcactc gaataccctc atttgacatg 540 agtgctaccc actattgcta tactcacaat gtgatattat ctggctgcag ggatcactcg 600 cactcatatc agtacctagc acttggcgtg cttcggacat ctgcaacagg gagggtattc 660 ttttctactc tgcgttccat taacctggat gacacccaaa accgaaagtc ttgcagtgtg 720 agtgcaactc ccttaggttg tgatatgctg tgctctaagg tcacagagac tgagaaagag 780 gattataatt cagctatccc aacatcgatg gtacatggaa ggttagggtt cgacggccaa 840 taccatgaga aggacctaga tgtcacaaca ctattcggag actgggtggc gaattaccca 900 ggagtagggg gtggatcctt tattgacaat cgcgtgtggt tcccagtata tggagggcta 960 aaacccaact cgcctagtga cactgcgcaa gaagggaaat atgtaatata caagcgatac 1020 aatgacacat gtccagatga gcaagattac cagattcgaa tggctaagtc ttcgtataag 1080 cctgggcggt tcggtgggaa acgcgtgcaa caggccatct tatctatcaa agtgtctaca 1140 tccttgggcg aagacccggt gctgactata ccgcccaaca caatcacact catgggggct 1200 gaaggcagag ttctcacagt agggacatct cacttcttgt atcaacgagg gtcatcatac 1260 ttctctcctg ccttattata tcctatgaca gtcagcaaca aaacagccac tcttcatagt 1320 ccttatacat tcaacgcctt cactcgacca ggtagtgtcc cttgccaggc ttcagcaaga 1380 tgccctaatt catgtgttac cggagtctat actgatccat atcccttagt cttttatagg 1440 aaccatacct tgcgaggagt attcggaaca atgcttgatg atgaacaagc aagactcaac 1500 cctgtatctg cagtattcga cagcatatcc cgcagtcgca taacccgggt gagttcaagc 1560 agcaccaagg cagcatacac gacatcaacg tgttttaaag ttgtcaagac caataaaacc 1620 tattgtctca gcattgctga aatatccaac accctcttcg gggaattcag aattgtccct 1680 ttactagttg agattctcaa ggatgatggg gtcagagagg ccaggtctgg tcgattgagt 1740 cagctgcaag agggttggaa ggatgacatt gtatcaccta tcttttgtga cactaagaat 1800 caaactgaat accggcgtga gctcgagtct tacgctgcca gctggccata a 1851 <210> 12 <211> 1851 <212> DNA <213> Newcastle disease virus <400> 12 atggaccgcg cagttagcca agttgcgtta gagaatgatg aaagagaggc aaagaataca 60 tggcgtttgg tattccggat cgcgatcctg cttttaacag ttgtgacctt agccatctct 120 gcagctgccc ttgcatatag tatggaggct agcacaccta gcgaccttat aggcataccg 180 actgcgatct ctagagcaga ggaaaggatt acatctgcac tcggttccaa ccaagatgta 240 gtagatagga tttataagca ggtggccctc gaatctccat tggcattgct aaacaccgaa 300 tctacaatta tgaatgcaat aacgtctctc tcttatcaga tcaatggggc cgcaaatagc 360 agcgggtgtg gggcacctat tcatgatccg gattatatcg agggaatagg taaagaactt 420 attgtggatg atgctagtga tgtcatatca ttctatccct ctgcgttcca agaacacctg 480 aactttatcc cggcgcctac tacaggatca ggttgcactc gaataccctc atttgatatg 540 agtgctaccc actactgcta tactcacaat gtgatattat ctggctgcag ggatcactcg 600 cactcacatc agtacttagc acttggcgtg cttcggacat ctgcaacagg gagggtattc 660 ttttctactc tgcgttccat taacctggat gacacccaaa atcgaaagtc ttgcagtgtg 720 agtgcaactc ccttaggttg tgatatgctg tgctctaagg tcacagagac tgaggaagag 780 gattataatt cagctatccc aacatcgatg gtacatggga ggttagggtt cgacggccaa 840 taccatgaga aggacctaga cgtcacaaca ctattcggag actgggtggc gaattaccca 900 ggagtagggg gtggatcctt tattgacaac cgcgtgtggt tcccagttta tggagggcta 960 aaacccaact cgcctagtga cactgcacaa gaagggaaat atgtaatata taagcgatac 1020 aatgacacat gtccagatga gcaagattac cagattcgaa tggctaagtc ttcgtataag 1080 cctgggcggt tcggtgggaa acgcgtgcaa caggccatct tatctatcaa agtgtctaca 1140 tccttgggcg aagacccggt gctgactgta ccgcccaaca cagtcacact catgggggct 1200 gaaggcagag ttctcacagt agggacatct catttcttgt accaacgagg gtcatcatac 1260 ttctctcctg ccttattata tcctatgaca gtcagcaaca aaacagccac tcttcatagt 1320 ccttatacat tcaatgcctt cactcgacca ggtagtgtcc cttgccaggc ttcagcaaga 1380 tgccctaatt catgtgttac cggagtctat actgatccat atcccttagt attttatagg 1440 aaccatacct tgcgaggagt attcgggaca atgcttgatg atgaacaagc aagactcaac 1500 cctgtatctg cagtattcga cagcatatcc cgcagtcgca taacccgggt gagttcaagc 1560 agcaccaagg cagcgtacac gacatcaacg tgttttaaag ttgtcaagac caataaaacc 1620 tattgtctca gcattgctga aatatccaac accctcttcg gggaattcag aattgtccct 1680 ttactagttg agattctcaa ggatgatggg gtcagagagg ccaggtctgg ccgattgagt 1740 cagctgcaag agggttggaa agatgacatt gtatcaccta tcttttgtga tattaagaat 1800 caaactgaat accggcatga gatcgagtct tacgctgcca gctggccgta a 1851 <110> Choong Ang Vaccine Lab.          Chungbuk National University Industry Academic Cooperation Foundation <120> A LENTOGENIC NEWCASTLE DISEASE VIRUS AND VACCINE CONTAINING THE          SAME <130> IPDC-37843 <150> KR 2010/085684 <151> 2010-09-01 <160> 12 <170> KopatentIn 2.0 <210> 1 <211> 553 <212> PRT <213> Newcastle disease virus <400> 1 Met Gly Ser Arg Ser Ser Thr Arg Ile Pro Val Pro Leu Met Leu Thr   1 5 10 15 Val Arg Val Ala Leu Ala Leu Cys Cys Val Arg Leu Thr Ser Ser Leu              20 25 30 Asp Gly Arg Pro Leu Ala Ala Ala Gly Ile Val Val Thr Gly Asp Lys          35 40 45 Ala Val Asn Ile Tyr Thr Ser Ser Gln Thr Gly Ser Ile Ile Val Lys      50 55 60 Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Ala Cys Ala Lys Ala Pro  65 70 75 80 Leu Glu Ala Tyr Asn Arg Thr Leu Thr Thr Leu Leu Thr Pro Leu Gly                  85 90 95 Asp Ser Ile Arg Arg Ile Gln Glu Ser Val Thr Thr Ser Gly Gly Gly             100 105 110 Lys Gln Gly Arg Leu Ile Gly Ala Ile Ile Gly Gly Ala Ala Leu Gly         115 120 125 Val Ala Thr Ala Ala Gln Ile Thr Ala Ala Ser Ala Leu Ile Gln Ala     130 135 140 Asn Gln Asn Ala Ala Asn Ile Leu Arg Leu Lys Glu Ser Ile Ala Ala 145 150 155 160 Thr Asn Glu Ala Val His Glu Val Thr Asp Gly Leu Ser Gln Leu Ala                 165 170 175 Val Ala Val Gly Lys Met Gln Gln Phe Val Asn Asp Gln Phe Asn Lys             180 185 190 Thr Ala Gln Glu Leu Asp Cys Ile Lys Ile Thr Gln Gln Val Gly Val         195 200 205 Glu Leu Asn Leu Tyr Leu Thr Glu Leu Thr Thr Val Phe Gly Pro Gln     210 215 220 Ile Thr Ser Pro Ala Leu Thr Gln Leu Thr Ile Gln Ala Leu Tyr Asn 225 230 235 240 Leu Ala Gly Gly Asn Met Asp Tyr Leu Leu Thr Lys Leu Gly Val Gly                 245 250 255 Asn Asn Gln Leu Ser Ser Leu Ile Gly Ser Gly Leu Ile Thr Gly Asn             260 265 270 Pro Ile Leu Tyr Asp Ser Gln Thr Gln Leu Leu Gly Ile Gln Val Thr         275 280 285 Leu Pro Ser Val Gly Asn Leu Asn Asn Met Arg Ala Thr Tyr Leu Glu     290 295 300 Thr Leu Ser Val Ser Thr Thr Lys Gly Phe Ala Ser Ala Leu Val Pro 305 310 315 320 Lys Val Val Thr Gln Val Gly Ser Val Ile Glu Glu Leu Asp Thr Ser                 325 330 335 Tyr Cys Ile Glu Thr Asp Leu Asp Leu Tyr Cys Thr Arg Ile Val Thr             340 345 350 Phe Pro Met Ser Pro Gly Ile Tyr Ser Cys Leu Ser Gly Asn Thr Ser         355 360 365 Ala Cys Met Tyr Ser Lys Thr Glu Gly Ala Leu Thr Thr Pro Tyr Met     370 375 380 Thr Leu Lys Gly Ser Val Ile Ala Asn Cys Lys Met Thr Thr Cys Arg 385 390 395 400 Cys Ala Asp Pro Pro Gly Ile Ile Ser Gln Asn Tyr Gly Glu Ala Val                 405 410 415 Ser Leu Ile Asp Arg Gln Ser Cys Asn Ile Leu Ser Leu Asp Gly Ile             420 425 430 Thr Leu Arg Leu Ser Gly Glu Phe Asp Ala Thr Tyr Gln Lys Asn Ile         435 440 445 Ser Ile Gln Asp Ser Gln Val Ile Val Thr Gly Asn Leu Asp Ile Ser     450 455 460 Thr Glu Leu Gly Asn Val Asn Asn Ser Ile Ser Asn Ala Leu Asp Lys 465 470 475 480 Leu Glu Glu Ser Asn Ser Lys Leu Asp Lys Val Asn Val Lys Leu Thr                 485 490 495 Ser Thr Ser Ala Leu Ile Thr Tyr Ile Val Leu Thr Ala Ile Ser Leu             500 505 510 Val Cys Gly Ile Leu Ser Leu Val Leu Ala Cys Tyr Leu Met Tyr Lys         515 520 525 Gln Lys Ala Gln Gln Lys Thr Leu Leu Trp Leu Gly Asn Asn Thr Leu     530 535 540 Asp Gln Met Arg Ala Thr Thr Lys Met 545 550 <210> 2 <211> 553 <212> PRT <213> Newcastle disease virus <400> 2 Met Gly Ser Arg Ser Ser Thr Arg Ile Pro Val Pro Leu Met Leu Thr   1 5 10 15 Val Arg Val Ala Leu Ala Leu Cys Cys Val Arg Leu Thr Ser Ser Leu              20 25 30 Asp Gly Arg Pro Leu Ala Ala Ala Gly Ile Val Val Thr Gly Asp Lys          35 40 45 Ala Val Asn Ile Tyr Thr Ser Ser Gln Thr Gly Ser Ile Ile Val Lys      50 55 60 Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Ala Cys Ala Lys Ala Pro  65 70 75 80 Leu Glu Ala Tyr Asn Arg Thr Leu Thr Thr Leu Leu Thr Pro Leu Gly                  85 90 95 Asp Ser Ile Arg Arg Ile Gln Glu Ser Val Thr Thr Ser Gly Gly Gly             100 105 110 Lys Gln Gly Arg Leu Ile Gly Ala Ile Ile Gly Gly Ala Ala Leu Gly         115 120 125 Val Ala Thr Ala Ala Gln Ile Thr Ala Ala Ser Ala Leu Ile Gln Ala     130 135 140 Asn Gln Asn Ala Ala Asn Ile Leu Arg Leu Lys Glu Ser Ile Ala Ala 145 150 155 160 Thr Asn Glu Ala Val His Glu Val Thr Asp Gly Leu Ser Gln Leu Ala                 165 170 175 Val Ala Val Gly Lys Met Gln Gln Phe Val Asn Asp Gln Phe Asn Lys             180 185 190 Thr Ala Gln Glu Leu Asp Cys Ile Lys Ile Thr Gln Gln Val Gly Val         195 200 205 Glu Leu Asn Leu Tyr Leu Thr Glu Leu Thr Thr Val Phe Gly Pro Gln     210 215 220 Ile Thr Ser Pro Ala Leu Thr Gln Leu Thr Ile Gln Ala Leu Tyr Asn 225 230 235 240 Leu Ala Gly Gly Asn Met Asp Tyr Leu Leu Thr Lys Leu Gly Val Gly                 245 250 255 Asn Asn Gln Leu Ser Ser Leu Ile Gly Ser Gly Leu Ile Thr Gly Asn             260 265 270 Pro Ile Leu Tyr Asp Ser Gln Thr Gln Leu Leu Gly Ile Gln Val Thr         275 280 285 Leu Pro Ser Val Gly Asn Leu Asn Asn Met Arg Ala Thr Tyr Leu Glu     290 295 300 Thr Leu Ser Val Ser Thr Thr Lys Gly Phe Ala Ser Ala Leu Val Pro 305 310 315 320 Lys Val Val Thr Gln Val Gly Ser Val Ile Glu Glu Leu Asp Thr Ser                 325 330 335 Tyr Cys Ile Glu Thr Asp Leu Asp Leu Tyr Cys Thr Arg Ile Val Thr             340 345 350 Phe Pro Met Ser Pro Gly Ile Tyr Ser Cys Leu Ser Gly Asn Thr Ser         355 360 365 Ala Cys Met Tyr Ser Lys Thr Glu Gly Ala Leu Thr Thr Pro Tyr Met     370 375 380 Thr Leu Lys Gly Ser Val Ile Ala Asn Cys Lys Met Thr Thr Cys Arg 385 390 395 400 Cys Ala Asp Pro Pro Gly Ile Ile Ser Gln Asn Tyr Gly Glu Ala Val                 405 410 415 Ser Leu Ile Asp Arg Gln Ser Cys Asn Ile Leu Ser Leu Asp Gly Ile             420 425 430 Thr Leu Arg Leu Ser Gly Glu Phe Asp Ala Thr Tyr Gln Lys Asn Ile         435 440 445 Ser Ile Gln Asp Ser Gln Val Ile Val Thr Gly Asn Leu Asp Ile Ser     450 455 460 Thr Glu Leu Gly Asn Val Asn Asn Ser Ile Ser Asn Ala Leu Asp Lys 465 470 475 480 Leu Glu Glu Ser Asn Ser Lys Leu Asp Lys Val Asn Val Lys Leu Thr                 485 490 495 Ser Thr Ser Ala Leu Ile Thr Tyr Ile Val Leu Thr Val Ile Ser Leu             500 505 510 Val Cys Gly Ile Leu Ser Leu Val Leu Ala Cys Tyr Leu Met Tyr Lys         515 520 525 Gln Lys Ala Gln Gln Lys Thr Leu Leu Trp Leu Gly Asn Asn Thr Leu     530 535 540 Asp Gln Met Arg Ala Thr Thr Lys Met 545 550 <210> 3 <211> 553 <212> PRT <213> Newcastle disease virus <400> 3 Met Gly Ser Arg Ser Ser Thr Arg Ile Pro Val Pro Leu Met Leu Thr   1 5 10 15 Val Arg Val Ala Leu Ala Leu Ser Cys Val Arg Leu Thr Ser Ser Leu              20 25 30 Asp Gly Arg Pro Leu Ala Ala Ala Gly Ile Val Val Thr Gly Asp Lys          35 40 45 Ala Val Asn Ile Tyr Thr Ser Ser Gln Thr Gly Ser Ile Ile Val Lys      50 55 60 Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Ala Cys Ala Lys Ala Pro  65 70 75 80 Leu Glu Ala Tyr Asn Arg Thr Leu Thr Thr Leu Leu Thr Pro Leu Gly                  85 90 95 Asp Ser Ile Arg Arg Ile Gln Glu Ser Val Thr Thr Ser Gly Gly Gly             100 105 110 Lys Gln Gly Arg Leu Ile Gly Ala Ile Ile Gly Gly Ala Ala Leu Gly         115 120 125 Val Ala Thr Ala Ala Gln Ile Thr Ala Ala Ser Ala Leu Ile Gln Ala     130 135 140 Asn Gln Asn Ala Ala Asn Ile Leu Arg Leu Lys Glu Ser Ile Ala Ala 145 150 155 160 Thr Asn Glu Ala Val His Glu Val Thr Asp Gly Leu Ser Gln Leu Ala                 165 170 175 Val Ala Val Gly Lys Met Gln Gln Phe Val Asn Asp Gln Phe Asn Lys             180 185 190 Thr Ala Gln Glu Leu Asp Cys Ile Lys Ile Thr Gln Gln Val Gly Val         195 200 205 Glu Leu Asn Leu Tyr Leu Thr Glu Leu Thr Thr Val Phe Gly Pro Gln     210 215 220 Ile Thr Ser Pro Ala Leu Thr Gln Leu Thr Ile Gln Ala Leu Tyr Asn 225 230 235 240 Leu Ala Gly Gly Asn Met Asp Tyr Leu Leu Thr Lys Leu Gly Val Gly                 245 250 255 Asn Asn Gln Leu Ser Ser Leu Ile Ser Ser Gly Leu Ile Thr Gly Asn             260 265 270 Pro Ile Leu Tyr Asp Ser Gln Thr Gln Leu Leu Gly Ile Gln Val Thr         275 280 285 Leu Pro Ser Val Gly Asn Leu Asn Asn Met Arg Ala Thr Tyr Leu Glu     290 295 300 Thr Leu Ser Val Ser Thr Thr Lys Gly Phe Ala Ser Ala Leu Val Pro 305 310 315 320 Lys Val Val Thr Gln Val Gly Ser Val Ile Glu Glu Leu Asp Thr Ser                 325 330 335 Tyr Cys Ile Glu Thr Asp Leu Asp Leu Tyr Cys Thr Arg Ile Val Thr             340 345 350 Phe Pro Met Ser Pro Gly Ile Tyr Ser Cys Leu Ser Gly Asn Thr Ser         355 360 365 Ala Cys Met Tyr Ser Lys Thr Glu Gly Ala Leu Thr Thr Pro Tyr Met     370 375 380 Thr Leu Lys Gly Ser Val Ile Ala Asn Cys Lys Met Thr Thr Cys Arg 385 390 395 400 Cys Ala Asp Pro Pro Gly Ile Ile Ser Gln Asn Tyr Gly Glu Ala Val                 405 410 415 Ser Leu Ile Asp Lys Gln Ser Cys Asn Ile Leu Ser Leu Asp Gly Ile             420 425 430 Thr Leu Arg Leu Ser Gly Glu Phe Asp Ala Thr Tyr Gln Lys Asn Ile         435 440 445 Ser Ile Gln Asp Ser Gln Val Ile Val Thr Gly Asn Leu Asp Ile Ser     450 455 460 Thr Glu Leu Gly Asn Val Asn Asn Ser Ile Ser Asn Ala Leu Asp Lys 465 470 475 480 Leu Glu Glu Ser Asn Ser Lys Leu Asp Lys Val Asn Val Lys Leu Thr                 485 490 495 Ser Thr Ser Ala Leu Ile Thr Tyr Ile Val Leu Thr Val Ile Ser Leu             500 505 510 Val Cys Gly Ile Leu Ser Leu Val Leu Ala Cys Tyr Leu Met Tyr Lys         515 520 525 Gln Lys Ala Gln Gln Lys Thr Leu Leu Trp Leu Gly Asn Asn Thr Leu     530 535 540 Asp Gln Met Arg Ala Thr Thr Lys Ile 545 550 <210> 4 <211> 616 <212> PRT <213> Newcastle disease virus <400> 4 Met Asp Arg Ala Val Ser Gln Val Ala Leu Glu Asn Asp Glu Arg Glu   1 5 10 15 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Ile Leu Leu Leu              20 25 30 Thr Val Val Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr Ser Met          35 40 45 Glu Ala Ser Thr Pro Ser Asp Leu Val Gly Ile Pro Thr Ala Ile Ser      50 55 60 Arg Ala Glu Glu Arg Ile Thr Ser Ala Leu Gly Ser Asn Gln Asp Val  65 70 75 80 Val Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu                  85 90 95 Leu Asn Thr Glu Ser Thr Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr             100 105 110 Gln Ile Asn Arg Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Ile His         115 120 125 Asp Pro Asp Tyr Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp     130 135 140 Ala Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Phe Gln Glu His Leu 145 150 155 160 Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro                 165 170 175 Ser Phe Asp Met Ser Ala Thr His Tyr Cys Tyr Thr His Asn Val Ile             180 185 190 Leu Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu         195 200 205 Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu     210 215 220 Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val 225 230 235 240 Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu                 245 250 255 Thr Glu Lys Glu Asp Tyr Asn Ser Ala Ile Pro Thr Ser Met Val His             260 265 270 Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Val         275 280 285 Thr Thr Leu Phe Gly Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly     290 295 300 Gly Ser Phe Ile Asp Asn Arg Val Trp Phe Pro Val Tyr Gly Gly Leu 305 310 315 320 Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile                 325 330 335 Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile             340 345 350 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg         355 360 365 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Glu     370 375 380 Asp Pro Val Leu Thr Ile Pro Pro Asn Thr Ile Thr Leu Met Gly Ala 385 390 395 400 Glu Gly Arg Val Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg                 405 410 415 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Ser             420 425 430 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr         435 440 445 Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser     450 455 460 Cys Val Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Val Phe Tyr Arg 465 470 475 480 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Glu Gln                 485 490 495 Ala Arg Leu Asn Pro Val Ser Ala Val Phe Asp Ser Ile Ser Arg Ser             500 505 510 Arg Ile Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr         515 520 525 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser     530 535 540 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro 545 550 555 560 Leu Leu Val Glu Ile Leu Lys Asp Asp Gly Val Arg Glu Ala Arg Ser                 565 570 575 Gly Arg Leu Ser Gln Leu Gln Glu Gly Trp Lys Asp Asp Ile Val Ser             580 585 590 Pro Ile Phe Cys Asp Thr Lys Asn Gln Thr Glu Tyr Arg Arg Glu Leu         595 600 605 Glu Ser Tyr Ala Ala Ser Trp Pro     610 615 <210> 5 <211> 616 <212> PRT <213> Newcastle disease virus <400> 5 Met Asp Arg Ala Val Ser Gln Val Ala Leu Glu Asn Asp Glu Arg Glu   1 5 10 15 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Ile Leu Leu Leu              20 25 30 Thr Val Val Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr Ser Met          35 40 45 Glu Ala Ser Thr Pro Ser Asp Leu Val Gly Ile Pro Thr Ala Ile Ser      50 55 60 Arg Ala Glu Glu Arg Ile Thr Ser Ala Leu Gly Ser Asn Gln Asp Val  65 70 75 80 Val Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu                  85 90 95 Leu Asn Thr Glu Ser Thr Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr             100 105 110 Gln Ile Asn Gly Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Ile His         115 120 125 Asp Pro Asp Tyr Ile Gly Gly Ile Gly Lys Glu Leu Ile Val Asp Asp     130 135 140 Ala Ser Asp Val Thr Ser Phe Tyr Pro Ser Ala Phe Gln Glu His Leu 145 150 155 160 Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro                 165 170 175 Ser Phe Asp Met Ser Ala Thr His Tyr Cys Tyr Thr His Asn Val Ile             180 185 190 Leu Ser Gly Cys Arg Asp His Ser His Ser Tyr Gln Tyr Leu Ala Leu         195 200 205 Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu     210 215 220 Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val 225 230 235 240 Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu                 245 250 255 Thr Glu Lys Glu Asp Tyr Asn Ser Ala Ile Pro Thr Ser Met Val His             260 265 270 Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Val         275 280 285 Thr Thr Leu Phe Gly Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly     290 295 300 Gly Ser Phe Ile Asp Asn Arg Val Trp Phe Pro Val Tyr Gly Gly Leu 305 310 315 320 Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile                 325 330 335 Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile             340 345 350 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg         355 360 365 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Glu     370 375 380 Asp Pro Val Leu Thr Ile Pro Pro Asn Thr Ile Thr Leu Met Gly Ala 385 390 395 400 Glu Gly Arg Val Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg                 405 410 415 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Ser             420 425 430 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr         435 440 445 Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser     450 455 460 Cys Val Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Val Phe Tyr Arg 465 470 475 480 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Glu Gln                 485 490 495 Ala Arg Leu Asn Pro Val Ser Ala Val Phe Asp Ser Ile Ser Arg Ser             500 505 510 Arg Ile Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr         515 520 525 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser     530 535 540 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro 545 550 555 560 Leu Leu Val Glu Ile Leu Lys Asp Asp Gly Val Arg Glu Ala Arg Ser                 565 570 575 Gly Arg Leu Ser Gln Leu Gln Glu Gly Trp Lys Asp Asp Ile Val Ser             580 585 590 Pro Ile Phe Cys Asp Thr Lys Asn Gln Thr Glu Tyr Arg Arg Glu Leu         595 600 605 Glu Ser Tyr Ala Ala Ser Trp Pro     610 615 <210> 6 <211> 616 <212> PRT <213> Newcastle disease virus <400> 6 Met Asp Arg Ala Val Ser Gln Val Ala Leu Glu Asn Asp Glu Arg Glu   1 5 10 15 Ala Lys Asn Thr Trp Arg Leu Val Phe Arg Ile Ala Ile Leu Leu Leu              20 25 30 Thr Val Val Thr Leu Ala Ile Ser Ala Ala Ala Leu Ala Tyr Ser Met          35 40 45 Glu Ala Ser Thr Pro Ser Asp Leu Ile Gly Ile Pro Thr Ala Ile Ser      50 55 60 Arg Ala Glu Glu Arg Ile Thr Ser Ala Leu Gly Ser Asn Gln Asp Val  65 70 75 80 Val Asp Arg Ile Tyr Lys Gln Val Ala Leu Glu Ser Pro Leu Ala Leu                  85 90 95 Leu Asn Thr Glu Ser Thr Ile Met Asn Ala Ile Thr Ser Leu Ser Tyr             100 105 110 Gln Ile Asn Gly Ala Ala Asn Ser Ser Gly Cys Gly Ala Pro Ile His         115 120 125 Asp Pro Asp Tyr Ile Glu Gly Ile Gly Lys Glu Leu Ile Val Asp Asp     130 135 140 Ala Ser Asp Val Ile Ser Phe Tyr Pro Ser Ala Phe Gln Glu His Leu 145 150 155 160 Asn Phe Ile Pro Ala Pro Thr Thr Gly Ser Gly Cys Thr Arg Ile Pro                 165 170 175 Ser Phe Asp Met Ser Ala Thr His Tyr Cys Tyr Thr His Asn Val Ile             180 185 190 Leu Ser Gly Cys Arg Asp His Ser His Ser His Gln Tyr Leu Ala Leu         195 200 205 Gly Val Leu Arg Thr Ser Ala Thr Gly Arg Val Phe Phe Ser Thr Leu     210 215 220 Arg Ser Ile Asn Leu Asp Asp Thr Gln Asn Arg Lys Ser Cys Ser Val 225 230 235 240 Ser Ala Thr Pro Leu Gly Cys Asp Met Leu Cys Ser Lys Val Thr Glu                 245 250 255 Thr Glu Glu Glu Asp Tyr Asn Ser Ala Ile Pro Thr Ser Met Val His             260 265 270 Gly Arg Leu Gly Phe Asp Gly Gln Tyr His Glu Lys Asp Leu Asp Val         275 280 285 Thr Thr Leu Phe Gly Asp Trp Val Ala Asn Tyr Pro Gly Val Gly Gly     290 295 300 Gly Ser Phe Ile Asp Asn Arg Val Trp Phe Pro Val Tyr Gly Gly Leu 305 310 315 320 Lys Pro Asn Ser Pro Ser Asp Thr Ala Gln Glu Gly Lys Tyr Val Ile                 325 330 335 Tyr Lys Arg Tyr Asn Asp Thr Cys Pro Asp Glu Gln Asp Tyr Gln Ile             340 345 350 Arg Met Ala Lys Ser Ser Tyr Lys Pro Gly Arg Phe Gly Gly Lys Arg         355 360 365 Val Gln Gln Ala Ile Leu Ser Ile Lys Val Ser Thr Ser Leu Gly Glu     370 375 380 Asp Pro Val Leu Thr Val Pro Pro Asn Thr Val Thr Leu Met Gly Ala 385 390 395 400 Glu Gly Arg Val Leu Thr Val Gly Thr Ser His Phe Leu Tyr Gln Arg                 405 410 415 Gly Ser Ser Tyr Phe Ser Pro Ala Leu Leu Tyr Pro Met Thr Val Ser             420 425 430 Asn Lys Thr Ala Thr Leu His Ser Pro Tyr Thr Phe Asn Ala Phe Thr         435 440 445 Arg Pro Gly Ser Val Pro Cys Gln Ala Ser Ala Arg Cys Pro Asn Ser     450 455 460 Cys Val Thr Gly Val Tyr Thr Asp Pro Tyr Pro Leu Val Phe Tyr Arg 465 470 475 480 Asn His Thr Leu Arg Gly Val Phe Gly Thr Met Leu Asp Asp Glu Gln                 485 490 495 Ala Arg Leu Asn Pro Val Ser Ala Val Phe Asp Ser Ile Ser Arg Ser             500 505 510 Arg Ile Thr Arg Val Ser Ser Ser Ser Thr Lys Ala Ala Tyr Thr Thr         515 520 525 Ser Thr Cys Phe Lys Val Val Lys Thr Asn Lys Thr Tyr Cys Leu Ser     530 535 540 Ile Ala Glu Ile Ser Asn Thr Leu Phe Gly Glu Phe Arg Ile Val Pro 545 550 555 560 Leu Leu Val Glu Ile Leu Lys Asp Asp Gly Val Arg Glu Ala Arg Ser                 565 570 575 Gly Arg Leu Ser Gln Leu Gln Glu Gly Trp Lys Asp Asp Ile Val Ser             580 585 590 Pro Ile Phe Cys Asp Ile Lys Asn Gln Thr Glu Tyr Arg His Glu Ile         595 600 605 Glu Ser Tyr Ala Ala Ser Trp Pro     610 615 <210> 7 <211> 1662 <212> DNA <213> Newcastle disease virus <400> 7 atgggctcca gatcttctac caggatccca gtacctctga tgctgactgt tcgggtcgcg 60 ctggcattgt gttgcgtccg tctgacaagc tcccttgatg gcaggcctct tgcagctgca 120 gggattgtgg taacaggaga caaagcagtc aacatataca cctcatccca gacagggtcg 180 atcatagtca agttactccc caatatgccc aaggacaaag aggcatgtgc aaaagccccg 240 ttggaggcat acaacaggac attgactact ctgctcaccc cccttggtga ttctatccgt 300 aggatacaag agtccgtgac tacatctgga ggagggaaac agggacgcct tataggcgct 360 attatcggtg gtgcggctct cggggttgca accgctgcac agataacagc agcctcggct 420 ctgatacagg ccaaccaaaa tgctgccaac attctccgac ttaaagagag cattgctgca 480 accaatgagg ctgtgcacga agtcactgac ggattatcac aactggccgt ggcagtcggg 540 aagatgcaac aatttgttaa tgaccagttt aataaaacag ctcaggaatt ggactgtata 600 aaaattacac agcaggttgg tgtagaactc aacttgtacc taactgaatt gactacagta 660 ttcgggccac aaatcacttc ccctgcccta acccagctga ccatccaggc actttataat 720 ctagctggtg ggaatatgga ttacttgttg acaaagttag gtgtagggaa caaccaactt 780 agctcattaa ttggtagcgg cctgatcacc ggcaatccta tcttgtacga ctcacagact 840 cagctcttgg gtatacaggt aaccctaccc tcagtcggga acctgaataa tatgcgtgcc 900 acctacttgg aaactttgtc tgtaagtaca accaaaggat ttgcctcagc acttgtccca 960 aaggtggtga cacaagtcgg ttccgtgata gaagaacttg acacctcata ctgcatagag 1020 accgatttag atttatattg tacaagaata gtgacattcc ctatgtctcc tggtatttac 1080 tcctgtttga gcggcaatac atcggcttgt atgtattcga agactgaggg tgcactcact 1140 acaccgtaca tgactctcaa aggctcggtt attgccaact gtaagatgac aacatgtaga 1200 tgtgcagacc ccccgggtat catatcgcag aattatggag aagctgtgtc tctaatagat 1260 aggcaatcat gcaatatctt atccttggac gggataactt tgaggctcag tggggaattt 1320 gatgcaactt atcaaaagaa tatctcaata caagattctc aagtaatcgt gacaggcaat 1380 ctcgatatct caactgagct tgggaatgtt aacaactcga taagtaatgc tctagataag 1440 ttagaggaaa gcaacagcaa actagacaag gtcaatgtca aactgaccag cacatctgcc 1500 ctcatcacct atattgttct aactgccata tctcttgttt gcggcatact tagcttggtt 1560 ctagcgtgct acctgatgta caagcaaaag gcgcaacaga agactctgtt atggcttggg 1620 aataataccc tggaccaaat gagggccact acaaaaatgt ga 1662 <210> 8 <211> 1662 <212> DNA <213> Newcastle disease virus <400> 8 atgggctcca gatcttctac caggatccca gtacctctga tgctgactgt tcgggtcgcg 60 ctggcactgt gttgcgtccg tctgacaagc tcccttgatg gcaggcctct tgcagctgca 120 gggattgtgg taacaggaga caaagcagtc aacatataca cctcatccca gacagggtcg 180 atcatagtca agttactccc caatatgccc aaggacaaag aggcatgtgc aaaagccccg 240 ttagaggcgt acaacaggac attgactact ctgctcaccc cccttggtga ttctatccgt 300 aggatacaag agtccgtgac tacatctgga ggagggaaac agggacgcct tataggcgct 360 attatcggtg gtgcggctct cggggttgca accgctgcac agataacagc agcctcggct 420 ctgatacaag ccaaccaaaa tgctgccaac attctccgac ttaaagagag cattgctgca 480 accaatgagg ctgtgcacga agtcactgac ggattatcac aactagccgt ggcagtcggg 540 aagatgcaac aatttgttaa tgaccagttt aataaaacag ctcaggaatt ggactgtata 600 aaaattacac agcaggttgg tgtagaactc aacctgtacc taactgaatt gactacagta 660 ttcgggccac aaatcacttc ccctgcctta acccagctga ccatccaggc actttataat 720 ctagctggtg ggaatatgga ttacttgttg acaaagttag gtgtagggaa caaccaactt 780 agctcattaa ttggtagcgg cctgatcacc ggcaacccta tcttgtacga ctcacagact 840 cagctcttgg gtatacaggt aaccctaccc tcagtcggga acctgaataa tatgcgtgcc 900 acctacttgg aaaccttgtc tgtaagtaca accaaaggat ttgcctcagc acttgtccca 960 aaggtggtga cacaagtcgg ttccgtgata gaagaacttg acacctcata ctgcatagag 1020 accgatttag atttatattg tacaagaata gtgacattcc ctatgtctcc tggtatttac 1080 tcctgtttga gcggcaatac atcggcctgt atgtattcga agactgaggg cgcactcact 1140 acaccgtaca tgactctcaa aggctcggtt attgccaact gtaagatgac aacatgtaga 1200 tgtgcagacc ccccgggtat catatcgcag aattatggag aagctgtgtc tctaatagat 1260 aggcaatcat gcaatatctt atccttggac gggataactt tgaggctcag tggggaattt 1320 gatgcaactt atcaaaagaa catctcaata caagattctc aagtaatcgt gacaggcaat 1380 ctcgatatct caactgagct tgggaatgtt aacaactcga taagtaatgc tctagataag 1440 ttagaggaaa gcaacagcaa actagacaag gtcaatgtca aactgaccag cacatctgcc 1500 ctcatcacct atattgttct aactgtcata tctcttgttt gcggcatact tagcctggtt 1560 ctagcatgct acctgatgta caagcaaaag gcgcaacaga agaccttgtt atggcttggg 1620 aataataccc tggaccaaat gagggccact acaaaaatgt ga 1662 <210> 9 <211> 1662 <212> DNA <213> Newcastle disease virus <400> 9 atgggctcca gatcttctac caggatccca gtacctctga tgctgactgt ccgggtcgcg 60 ctggcactga gttgcgtccg tctgacaagc tcccttgatg gcaggcctct tgcagctgca 120 gggattgtgg taacaggaga caaagcagtc aacatataca cctcatccca gacagggtcg 180 atcatagtca agttactccc caatatgccc aaggacaaag aggcgtgtgc aaaagcccca 240 ttggaggcgt acaacaggac attgactact ctgctcaccc cccttggtga ttctatccgt 300 aggatacaag agtccgtgac tacatctgga ggagggaaac aggggcgcct tataggcgct 360 attatcggtg gtgcggctct cggggttgca accgctgcac agataacagc agcctcggct 420 ttgatacaag ccaaccaaaa tgctgctaac atcctccggc ttaaagagag cattgctgca 480 accaatgagg ctgtgcacga agtcactgac ggattatcac aactagccgt ggcagtcggg 540 aagatgcaac aatttgttaa tgaccagttt aacaaaacag ctcaggaatt ggactgtata 600 aaaattacac agcaggttgg tgtagaactc aacctgtacc taactgaatt gactacagta 660 ttcgggccac aaatcacctc ccctgctcta acccagctga ctatccaggc actttataat 720 ctagctggtg ggaatatgga ttacttgttg acaaagttag gtgtagggaa caaccaactc 780 agctcattaa ttagtagcgg cctgatcacc ggcaacccta tcctgtacga ctcacagact 840 cagctcctgg gtatacaggt aaccctaccc tcagttggga acctgaataa tatgcgtgcc 900 acctacctgg aaactttgtc tgtaagtaca accaaaggat ttgcctcagc acttgtccca 960 aaggtggtga cacaggtcgg ttccgtgata gaagaacttg acacctcata ctgtatagag 1020 accgatttag atctatattg tacaagaata gtgacattcc ctatgtctcc tggtatttac 1080 tcctgtttga gcggcaatac atcggcttgt atgtattcga agactgaggg cgcactcact 1140 acgccgtaca tgaccctcaa aggctcggtt attgccaact gtaagatgac aacatgtaga 1200 tgtgcagacc ccccgggtat catatcgcaa aattatggag aagctgtgtc tctaatagat 1260 aagcaatcgt gcaatatctt atccttggac gggataactt tgaggctcag tggggaattt 1320 gatgcaactt atcaaaagaa tatctcgata caagattctc aagtaatcgt gacaggcaat 1380 ctcgatatct cgactgagct tgggaatgtt aacaactcga taagtaatgc tctagataag 1440 ttagaggaaa gcaacagcaa actagacaag gtcaatgtca aactgaccag cacgtctgcc 1500 ctcatcacct acattgtttt aactgtcata tctcttgttt gcggtatact tagcctggtt 1560 ctagcatgct acctgatgta caagcaaaag gcgcaacaga agaccttgtt atggcttggg 1620 aataataccc tggaccagat gagggccact acgaaaatat ga 1662 <210> 10 <211> 1851 <212> DNA <213> Newcastle disease virus <400> 10 atggaccgcg cagttagcca agttgcgtta gagaatgatg agagagaggc aaagaataca 60 tggcgtttgg tattccggat cgcgatcctg cttctaacag ttgtgacctt agccatctct 120 gcagctgccc tcgcgtatag tatggaggct agcacaccta gcgaccttgt aggcataccg 180 actgcgatct ctagagcaga ggaaaggatt acatctgcac tcggttccaa ccaagatgta 240 gtagatagga tttataagca ggtggccctc gaatctccat tggcattgtt aaacaccgag 300 tctacaatta tgaatgcaat aacgtctctc tcttatcaga tcaatagggc tgcaaatagc 360 agcgggtgtg gggcgcctat tcatgatccg gattatatcg ggggaatagg taaagaactt 420 attgtagatg atgctagtga tgtcacttca ttctatccct ctgcgttcca agaacacctg 480 aactttatcc cggcgcctac tacaggatca ggttgcactc gaataccctc atttgacatg 540 agtgctaccc actattgtta tactcacaat gtgatattat ctggctgcag ggatcactcg 600 cactcacatc agtacctagc acttggcgtg cttcggacat ctgcaacagg gagggtattc 660 ttttctactc tgcgttccat taacctggat gacacccaaa accgaaagtc ttgcagtgtg 720 agtgcaactc ccttaggttg tgatatgctg tgctctaagg tcacagagac tgagaaagag 780 gattataact cagctatccc aacatcgatg gtacatggaa ggttagggtt cgacggccaa 840 taccatgaga aggacctaga tgtcacaaca ctattcggag actgggtggc gaattaccca 900 ggagtggggg gtggatcctt tattgacaac cgcgtgtggt tcccagttta tggagggcta 960 aaacccaact cgcctagtga cactgcacaa gaagggaaat atgtaatata caagcgatac 1020 aatgacacat gtccagatga gcaagattac cagattcgaa tggctaagtc ttcgtacaag 1080 cctgggcggt ttggtgggaa acgcgtgcaa caggccatct tatctatcaa agtgtctaca 1140 tccttgggcg aagacccggt gctgactata ccgcccaaca caatcacact catgggggct 1200 gaaggcagag ttctcacagt agggacatct cacttcttgt atcaacgagg gtcatcatac 1260 ttctctcctg ccttattata tcctatgaca gtcagcaaca aaacagccac tcttcatagt 1320 ccttatacat tcaacgcctt cactcgacca ggtagtgtcc cttgccaggc ttcagcaaga 1380 tgccctaatt catgtgttac cggggtctat actgatccat atcccttagt cttttatagg 1440 aaccatacct tgcgaggagt attcggaaca atgcttgatg atgaacaagc aagactcaac 1500 cctgtatctg cagtattcga cagcatatcc cgcagtcgca taacccgggt gagttcaagc 1560 agcaccaagg cagcatacac gacatcaacg tgttttaaag ttgtcaagac caataaaacc 1620 tattgtctca gcattgctga aatatccaac accctcttcg gggaattcag aattgtccct 1680 ttactagttg agattctcaa ggatgatggg gtcagagagg ccaggtctgg ccgattgagt 1740 cagctgcaag agggttggaa ggatgacatt gtatcaccta tcttttgtga cactaagaat 1800 caaactgaat accggcgtga gctcgagtct tatgctgcca gctggccata a 1851 <210> 11 <211> 1851 <212> DNA <213> Newcastle disease virus <400> 11 atggaccgcg cagttagcca agttgcgtta gagaatgatg agagagaggc aaagaataca 60 tggcgtttgg tattccggat cgcgatcctg cttctaacag ttgtgacctt agccatctct 120 gcagctgccc ttgcgtatag tatggaggct agcacaccta gcgaccttgt aggcataccg 180 actgcgatct ctagagcaga ggaaaggatt acatctgcac tcggttccaa ccaagatgta 240 gtagatagga tttataagca ggtggccctc gaatctccat tggcattgct aaacaccgag 300 tctacaatta tgaatgcaat aacgtctctc tcttatcaga tcaatggggc cgcaaatagc 360 agcgggtgtg gggcacctat tcatgatccg gattatatcg ggggaatagg taaagaactt 420 attgtagatg atgctagtga tgtcacatca ttctatccct ctgcgttcca agaacacctg 480 aactttatcc cggcgcctac tacaggatca ggttgcactc gaataccctc atttgacatg 540 agtgctaccc actattgcta tactcacaat gtgatattat ctggctgcag ggatcactcg 600 cactcatatc agtacctagc acttggcgtg cttcggacat ctgcaacagg gagggtattc 660 ttttctactc tgcgttccat taacctggat gacacccaaa accgaaagtc ttgcagtgtg 720 agtgcaactc ccttaggttg tgatatgctg tgctctaagg tcacagagac tgagaaagag 780 gattataatt cagctatccc aacatcgatg gtacatggaa ggttagggtt cgacggccaa 840 taccatgaga aggacctaga tgtcacaaca ctattcggag actgggtggc gaattaccca 900 ggagtagggg gtggatcctt tattgacaat cgcgtgtggt tcccagtata tggagggcta 960 aaacccaact cgcctagtga cactgcgcaa gaagggaaat atgtaatata caagcgatac 1020 aatgacacat gtccagatga gcaagattac cagattcgaa tggctaagtc ttcgtataag 1080 cctgggcggt tcggtgggaa acgcgtgcaa caggccatct tatctatcaa agtgtctaca 1140 tccttgggcg aagacccggt gctgactata ccgcccaaca caatcacact catgggggct 1200 gaaggcagag ttctcacagt agggacatct cacttcttgt atcaacgagg gtcatcatac 1260 ttctctcctg ccttattata tcctatgaca gtcagcaaca aaacagccac tcttcatagt 1320 ccttatacat tcaacgcctt cactcgacca ggtagtgtcc cttgccaggc ttcagcaaga 1380 tgccctaatt catgtgttac cggagtctat actgatccat atcccttagt cttttatagg 1440 aaccatacct tgcgaggagt attcggaaca atgcttgatg atgaacaagc aagactcaac 1500 cctgtatctg cagtattcga cagcatatcc cgcagtcgca taacccgggt gagttcaagc 1560 agcaccaagg cagcatacac gacatcaacg tgttttaaag ttgtcaagac caataaaacc 1620 tattgtctca gcattgctga aatatccaac accctcttcg gggaattcag aattgtccct 1680 ttactagttg agattctcaa ggatgatggg gtcagagagg ccaggtctgg tcgattgagt 1740 cagctgcaag agggttggaa ggatgacatt gtatcaccta tcttttgtga cactaagaat 1800 caaactgaat accggcgtga gctcgagtct tacgctgcca gctggccata a 1851 <210> 12 <211> 1851 <212> DNA <213> Newcastle disease virus <400> 12 atggaccgcg cagttagcca agttgcgtta gagaatgatg aaagagaggc aaagaataca 60 tggcgtttgg tattccggat cgcgatcctg cttttaacag ttgtgacctt agccatctct 120 gcagctgccc ttgcatatag tatggaggct agcacaccta gcgaccttat aggcataccg 180 actgcgatct ctagagcaga ggaaaggatt acatctgcac tcggttccaa ccaagatgta 240 gtagatagga tttataagca ggtggccctc gaatctccat tggcattgct aaacaccgaa 300 tctacaatta tgaatgcaat aacgtctctc tcttatcaga tcaatggggc cgcaaatagc 360 agcgggtgtg gggcacctat tcatgatccg gattatatcg agggaatagg taaagaactt 420 attgtggatg atgctagtga tgtcatatca ttctatccct ctgcgttcca agaacacctg 480 aactttatcc cggcgcctac tacaggatca ggttgcactc gaataccctc atttgatatg 540 agtgctaccc actactgcta tactcacaat gtgatattat ctggctgcag ggatcactcg 600 cactcacatc agtacttagc acttggcgtg cttcggacat ctgcaacagg gagggtattc 660 ttttctactc tgcgttccat taacctggat gacacccaaa atcgaaagtc ttgcagtgtg 720 agtgcaactc ccttaggttg tgatatgctg tgctctaagg tcacagagac tgaggaagag 780 gattataatt cagctatccc aacatcgatg gtacatggga ggttagggtt cgacggccaa 840 taccatgaga aggacctaga cgtcacaaca ctattcggag actgggtggc gaattaccca 900 ggagtagggg gtggatcctt tattgacaac cgcgtgtggt tcccagttta tggagggcta 960 aaacccaact cgcctagtga cactgcacaa gaagggaaat atgtaatata taagcgatac 1020 aatgacacat gtccagatga gcaagattac cagattcgaa tggctaagtc ttcgtataag 1080 cctgggcggt tcggtgggaa acgcgtgcaa caggccatct tatctatcaa agtgtctaca 1140 tccttgggcg aagacccggt gctgactgta ccgcccaaca cagtcacact catgggggct 1200 gaaggcagag ttctcacagt agggacatct catttcttgt accaacgagg gtcatcatac 1260 ttctctcctg ccttattata tcctatgaca gtcagcaaca aaacagccac tcttcatagt 1320 ccttatacat tcaatgcctt cactcgacca ggtagtgtcc cttgccaggc ttcagcaaga 1380 tgccctaatt catgtgttac cggagtctat actgatccat atcccttagt attttatagg 1440 aaccatacct tgcgaggagt attcgggaca atgcttgatg atgaacaagc aagactcaac 1500 cctgtatctg cagtattcga cagcatatcc cgcagtcgca taacccgggt gagttcaagc 1560 agcaccaagg cagcgtacac gacatcaacg tgttttaaag ttgtcaagac caataaaacc 1620 tattgtctca gcattgctga aatatccaac accctcttcg gggaattcag aattgtccct 1680 ttactagttg agattctcaa ggatgatggg gtcagagagg ccaggtctgg ccgattgagt 1740 cagctgcaag agggttggaa agatgacatt gtatcaccta tcttttgtga tattaagaat 1800 caaactgaat accggcatga gatcgagtct tacgctgcca gctggccgta a 1851

Claims (23)

서열번호 1의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 F 단백질을 포함하는 뉴캐슬병 바이러스.Newcastle disease virus represented by the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 96% homology therewith and comprising an F protein having equivalent immunogenicity. 제 1항에 있어서,
상기 서열번호 1과 96% 이상 상동성을 가지는 아미노산 서열은 서열번호 2 또는 서열번호 3인 것을 특징으로 하는 뉴캐슬병 바이러스.The method of claim 1,
Newcastle disease virus, characterized in that the amino acid sequence having at least 96% homology with SEQ ID NO: 1 or SEQ ID NO: 2. 서열번호 1의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 F 단백질을 코딩하는 핵산을 포함하는 뉴캐슬병 바이러스.Newcastle disease virus represented by the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 96% homology therewith and comprising a nucleic acid encoding an F protein having equivalent immunogenicity. 제 3항에 있어서,
서열번호 2 또는 서열번호 3의 아미노산 서열을 코딩하는 핵산을 포함하는 뉴캐슬병 바이러스.The method of claim 3,
Newcastle disease virus comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3. 서열번호 4의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 HN 단백질을 포함하는 뉴캐슬병 바이러스.Newcastle disease virus represented by the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 96% homology therewith and comprising an HN protein having equivalent immunogenicity. 제 5항에 있어서,
상기 서열번호 4와 96% 이상 상동성을 가지는 아미노산 서열은 서열번호 5 또는 서열번호 6인 것을 특징으로 하는 뉴캐슬병 바이러스.6. The method of claim 5,
Newcastle disease virus, characterized in that the amino acid sequence having at least 96% homology with SEQ ID NO: 4 or SEQ ID NO: 6. 서열번호 4의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 HN 단백질을 코딩하는 핵산을 포함하는 뉴캐슬병 바이러스.Newcastle disease virus represented by the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 96% homology therewith and comprising a nucleic acid encoding an HN protein having equivalent immunogenicity. 제 7항에 있어서,
서열번호 5 또는 서열번호 6의 아미노산 서열을 코딩하는 핵산을 포함하는 뉴캐슬병 바이러스.The method of claim 7, wherein
Newcastle disease virus comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6. 서열번호 1의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 F 단백질 및 서열번호 4의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 HN 단백질을 포함하는 뉴캐슬병 바이러스.Represented by an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 96% homology therewith, and represented by an F protein having an equivalent immunogenicity and an amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 96% homology thereto Newcastle disease virus comprising HN protein with equivalent immunogenicity. 제 9항에 있어서,
상기 서열번호 1의 아미노산 서열과 96% 이상 상동성을 가지는 아미노산 서열은 서열번호 2 또는 서열번호 3인 것을 특징으로 하는 뉴캐슬병 바이러스.The method of claim 9,
Newcastle disease virus, characterized in that the amino acid sequence having at least 96% homology with the amino acid sequence of SEQ ID NO: SEQ ID NO: 2 or SEQ ID NO: 3. 제 9항에 있어서,
상기 서열번호 4의 아미노산 서열과 96% 이상 상동성을 가지는 아미노산 서열은 서열번호 5 또는 서열번호 6인 것을 특징으로 하는 뉴캐슬병 바이러스.The method of claim 9,
Newcastle disease virus, characterized in that the amino acid sequence having at least 96% homology with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 6. 서열번호 1의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 F 단백질을 코딩하는 핵산 및 서열번호 4의 아미노산 서열 또는 그와 96% 이상 상동성을 가지는 아미노산 서열로 표시되며 동등한 면역원성을 가지는 HN 단백질을 코딩하는 핵산을 포함하는 뉴캐슬병 바이러스.A nucleic acid encoding an F protein having an equivalent immunogenicity and an amino acid sequence of SEQ ID NO: 1 or 96% or more homologous thereto and an amino acid sequence of SEQ ID NO: 4 or an amino acid having 96% homology thereto Newcastle disease virus, which comprises a nucleic acid that encodes an HN protein expressed in sequence and having equivalent immunogenicity. 제 12항에 있어서,
서열번호 2 또는 서열번호 3의 아미노산 서열을 코딩하는 핵산을 포함하는 뉴캐슬병 바이러스.The method of claim 12,
Newcastle disease virus comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3. 제 12항에 있어서,
서열번호 5 또는 서열번호 6의 아미노산 서열을 코딩하는 핵산을 포함하는 뉴캐슬병 바이러스.The method of claim 12,
Newcastle disease virus comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6. 제1항 내지 제14항 중 어느 한 항의 바이러스를 포함하는 뉴캐슬병 바이러스용 백신.The vaccine for Newcastle disease virus containing the virus of any one of Claims 1-14. 제15항에 있어서,
상기 백신은 생백신, 약독화 백신, 또는 사독 백신인 것을 특징으로 하는 뉴캐슬병 바이러스용 백신.16. The method of claim 15,
The vaccine is a live vaccine, attenuated vaccine, or vaccine for Newcastle disease, characterized in that the deadly vaccine. 제15항에 있어서,
상기 백신은 닭, 꿩, 오리, 칠면조, 메추리 또는 타조에 투여하여 뉴캐슬병을 예방하는 것을 특징으로 하는 뉴캐슬병 바이러스용 백신.16. The method of claim 15,
The vaccine is a vaccine for Newcastle disease virus, characterized in that the administration of chicken, pheasant, duck, turkey, quail or ostrich to prevent Newcastle disease. 제15항의 백신을 인간을 제외한 개체에 투여하여 뉴캐슬병 바이러스 감염 질환을 예방 또는 치료하는 방법.A method of preventing or treating a Newcastle Disease Virus Infectious Disease by administering the vaccine of claim 15 to a subject other than a human. 제1항 내지 제14항 중 어느 한 항의 바이러스를 특이적으로 인식하는 항체.The antibody which specifically recognizes the virus of any one of Claims 1-14. 제19항에 따른 항체를 포함하는 뉴캐슬병 바이러스 진단용 조성물.Newcastle disease virus diagnostic composition comprising the antibody of claim 19. 제19항에 따른 항체를 포함하는 뉴캐슬병 바이러스 치료제.A Newcastle disease virus therapeutic agent comprising the antibody of claim 19. 제19항에 따른 항체를 뉴캐슬병 바이러스를 포함하는 시료에 반응시키고, 상기 항체에 대한 양성반응을 나타내는 시료를 뉴캐슬병으로 판단하는 것을 포함하는 뉴캐슬병 바이러스의 진단에 관한 정보를 제공하는 방법.20. A method of providing information regarding the diagnosis of Newcastle Disease Virus comprising reacting an antibody according to claim 19 to a sample comprising Newcastle Disease Virus and judging that the sample showing a positive response to the antibody is Newcastle Disease. 제19항에 따른 항체를 포함하는 뉴캐슬병 바이러스 진단용 키트.
Newcastle disease virus diagnostic kit comprising an antibody according to claim 19.
KR1020110088716A 2010-09-01 2011-09-01 A lentogenic newcastle disease virus and vaccine containing the same KR101371365B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100085684 2010-09-01
KR20100085684 2010-09-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020130119120A Division KR20130132704A (en) 2010-09-01 2013-10-07 A lentogenic newcastle disease virus and vaccine containing the same

Publications (2)

Publication Number Publication Date
KR20120024493A true KR20120024493A (en) 2012-03-14
KR101371365B1 KR101371365B1 (en) 2014-03-26

Family

ID=46131441

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020110088716A KR101371365B1 (en) 2010-09-01 2011-09-01 A lentogenic newcastle disease virus and vaccine containing the same
KR1020130119120A KR20130132704A (en) 2010-09-01 2013-10-07 A lentogenic newcastle disease virus and vaccine containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020130119120A KR20130132704A (en) 2010-09-01 2013-10-07 A lentogenic newcastle disease virus and vaccine containing the same

Country Status (1)

Country Link
KR (2) KR101371365B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110672844A (en) * 2019-10-29 2020-01-10 华中科技大学 Newcastle disease virus antibody magnetic immuno-chemiluminescence detection kit and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100454870B1 (en) * 2001-07-30 2004-11-03 주식회사 인트론바이오테크놀로지 F protein and HN protein of Newcastle disease virus strains and genes thereof
KR100776398B1 (en) * 2006-03-23 2007-11-28 주식회사 고려비엔피 HN epitope recognized by avian immune system and antigenic variant Newcastle disease viruses carrying changes in the epitope

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110672844A (en) * 2019-10-29 2020-01-10 华中科技大学 Newcastle disease virus antibody magnetic immuno-chemiluminescence detection kit and application thereof

Also Published As

Publication number Publication date
KR20130132704A (en) 2013-12-05
KR101371365B1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
RU2624037C2 (en) Constructs of recombinant nonpathogenic marek&#39;s disease virus coding antigens of infectious laryngotracheitis virus and newcastle disease virus
CN102428099B (en) The epiornitic seedling of delivery Avian pneumo-encephalitis virus
CN101514334B (en) Chicken infectivity bronchitis virus attenuated vaccine strain and application thereof
JP5442442B2 (en) Novel H5 proteins, nucleic acid molecules and vectors encoding them, and their pharmaceutical use
US20100150958A1 (en) Methods and Compositions for Use of a Coccidiosis Vaccine
KR20170032441A (en) Coronavirus
EP2630155B1 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
CN108884447B (en) Coronavirus
US20170348413A1 (en) Influenza h5 vaccines
KR20110092316A (en) Recombinant inactivated viral vector vaccine
US20200129614A1 (en) H52 ibv vaccine with heterologous spike protein
US20200129613A1 (en) 4/91 ibv vaccine with heterologous spike protein
KR101371365B1 (en) A lentogenic newcastle disease virus and vaccine containing the same
CN112410307A (en) Novel newcastle disease virus for encoding chicken infectious bursal disease virus VP2Y and application thereof in preparation of bio-adjuvant bivalent vaccine
US20160361409A1 (en) H5 proteins of h5n1 influenza virus for use as a medicament
US20090258035A1 (en) Avian virus vaccines and uses thereof
US10201604B2 (en) Live attenuated infectious laryngotracheitis virus (ILTV) vaccines and preparation thereof
KR20130130326A (en) Novel canine influenza virus(h3n2), composition comprising thereof and diagnostic kits of the novel canine h3n2 influenza virus
KR101258619B1 (en) New subtype vaccine strain of lentogenic Newcastle disease virus and the viral vaccine comprising thereof
Ghanem et al. Phylogenetic Analysis of Infectious Bronchitis Viruses Currently Circulating in the Egyptian Field
Bossman-Adotevi Molecular Characterisation of Newcastle Disease Virus from Different Agro-Ecological Zones in Ghana
KR20230153038A (en) Recombinant vector comprising genes encoding RANKL protein and immunological adjuvant and feed additive for chicken using the same
KR20110116315A (en) Avirulent infectious bursal disease virus and use thereof as a vaccine
Aston Effects of vaccination schedule and ambient ammonia on the immune response to vaccination and protection against homologous challenge in chickens

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
E902 Notification of reason for refusal
A107 Divisional application of patent
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20170112

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20180213

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20190226

Year of fee payment: 6

R401 Registration of restoration